ID	Upstream event	Relationship type	Downstream event5	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells	leads to	Reduction, Plasma 17beta-estradiol concentrations9	Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity	leads to	Decreased, Mitochondrial fatty acid beta-oxidation11	Inhibition, Acetylcholinesterase (AchE)	leads to	Accumulation, Acetylcholine in synapses16	Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways	leads to	Altered, Cardiovascular development/function17	Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways	leads to	Up Regulation, CYP1A118	Activation, AhR	leads to	Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways19	Activation, AhR	leads to	Up Regulation, CYP1A123	Alkylation, DNA	leads to	Increase, Heritable mutations in offspring24	Alkylation, DNA	leads to	N/A, Insufficient or incorrect DNA repair25	Alkylation, DNA	leads to	Increase, Mutations31	Agonism, Androgen receptor	leads to	Reduction, Gonadotropins, circulating concentrations32	Agonism, Androgen receptor	leads to	Reduction, Testosterone synthesis by ovarian theca cells33	N/A, Androgen receptor, Antagonism	leads to	Decreased, Transcription of genes by AR35	N/A, Androgen receptor, Antagonism	leads to	Alteration, Wnt pathway36	Reduction, Angiogenesis	leads to	Impairment, Endothelial network43	Decrease, Aromatase (Cyp19a1)	leads to	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells45	Inhibition, Aromatase	leads to	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells51	Induction, Ataxia, paralysis, or hyperactivity	leads to	Decrease, Population trajectory53	Up Regulation, Biliary excretion	leads to	Decrease, Serum thyroxine (T4)59	Reduction, Ca and HCO3 transport to shell gland	leads to	Reduction, Eggshell thickness60	Increase, Ca++ (intracellular)	leads to	Disruption, Mitochondrial electron transport chain61	Inhibition, Ca++ ATPase	leads to	Increase, Ca++ (intracellular)62	Decreased, Calcium influx	leads to	Impairment, Learning and memory66	Up Regulation, CD36	leads to	Increase, FA Influx67	N/A, Cell injury/death	leads to	Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)68	N/A, Cell injury/death	leads to	Activation, Stellate cells69	Proliferation, Cell proliferation in the absence of cytotoxicity	leads to	Hyperplasia, Hyperplasia70	Induction, Chitin degradation and resorption	leads to	Induction, Pre-mature molting73	Induction, Chitin synthesis	leads to	Induction, Pre-mature molting77	Activation, ChREBP	leads to	Synthesis, De Novo FA82	Accumulation, Collagen	leads to	N/A, Liver fibrosis85	Activation, Constitutive androstane receptor, NR1l3	leads to	Induction, Upregulation of glucuronyltransferase activity88	N/A, Covalent binding to protein, possibly lysine residue	leads to	Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways93	Production, Critical Metabolites (CGA 330050 and CGA 265307)	leads to	Induction, Liver “Dysfunctional” Changes by CGA 33005094	Reduction, Cumulative fecundity and spawning	leads to	Decrease, Population trajectory95	Inhibition, Cyclooxygenase activity	leads to	Reduction, Prostaglandin E2 concentration96	Up Regulation, CYP1A1	leads to	Peptide Oxidation104	Up Regulation, CYP1B1	leads to	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells108	Release, Cytokine	leads to	Increase, Inflammation110	Synthesis, De Novo FA	leads to	Accumulation, Triglyceride116	Activation, EcR	leads to	Induction, Chitin degradation and resorption118	Activation, EcR	leads to	Induction, Chitin synthesis123	Reduction, Eggshell thickness	leads to	N/A, Reproductive failure125	Impairment, Endothelial network	leads to	Insufficiency, Vascular126	Agonism, Estrogen receptor	leads to	Altered, Reproductive behaviour127	Agonism, Estrogen receptor	leads to	Impaired development of, Reproductive organs128	Agonism, Estrogen receptor	leads to	Increase, Vitellogenin synthesis in liver129	Antagonism, Estrogen receptor	leads to	Reduction, Vitellogenin synthesis in liver132	Increase, FA Influx	leads to	Accumulation, Triglyceride133	Activation, FAS	leads to	Synthesis, De Novo FA134	Accumulation, Fatty acid	leads to	Undefined, Liver Steatosis135	Reduction, Fecundity	leads to	Decline, Population136	N/A, Gap	leads to	Reduction, Ca and HCO3 transport to shell gland143	Reduction, Gonadotropins, circulating concentrations	leads to	Reduction, Testosterone synthesis by ovarian theca cells144	Depletion, GSH	leads to	N/A, Oxidative stress146	Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)	leads to	Peptide Oxidation147	Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)	leads to	Up Regulation, TGFbeta1 expression148	Increase, Hepatic transport of parent T4	leads to	Up Regulation, Biliary excretion149	Up Regulation, Hepatic transporter gene expression	leads to	Increase, Hepatic transport of parent T4154	Decreased, HSD17B10 expression	leads to	Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity158	Hyperplasia, Hyperplasia	leads to	Promotion, Hepatocelluar carcinoma159	Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307	leads to	Induction, Sustained Hepatotoxicity164	N/A, Insufficient or incorrect DNA repair	leads to	Increase, Mutations168	N/A, Interferences with SH-/selen-proteins	leads to	Depletion, GSH169	Increase, Liver and splenic hemosiderosis	leads to	N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number170	Induction, Liver “Dysfunctional” Changes by CGA 330050	leads to	Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307172	Activation, Long term AHR receptor driven direct and indirect gene expression changes	leads to	N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects173	Activation, LXR	leads to	Up Regulation, CD36174	Activation, LXR	leads to	Activation, ChREBP175	Activation, LXR	leads to	Activation, FAS176	Activation, LXR	leads to	Activation, SCD-1177	Activation, LXR	leads to	Activation, SREBP-1c182	N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number	leads to	N/A, Cyanosis occurs188	Disruption, Mitochondrial electron transport chain	leads to	Decrease, Mitochondrial ATP production189	Disruption, Mitochondrial electron transport chain	leads to	Increase, ROS production190	Decreased, Mitochondrial fatty acid beta-oxidation	leads to	Accumulation, Fatty acid194	Abnormal, Morphogenesis	leads to	Decreased, Fetal birth weight195	Abnormal, Morphogenesis	leads to	Increased, Functional deficits196	Abnormal, Morphogenesis	leads to	Increased, Lethality197	Abnormal, Morphogenesis	leads to	Increased, Structural malformations198	Increase, Mortality	leads to	Reduction, Fecundity199	Increase, Mortality	leads to	Decline, Population200	Increased, Mortality	leads to	Decline, Population202	Increase, Mutations	leads to	Increase, Heritable mutations in offspring203	Altered, Neuroanatomy	leads to	Altered, Neurophysiology207	N/A, Neurodegeneration	leads to	N/A, Neuroinflammation208	N/A, Neuroinflammation	leads to	N/A, Neurodegeneration210	N/A, Neuronal dysfunction	leads to	N/A, Neuroinflammation212	Decreased, Nitric Oxide	leads to	Decreased, Long-term potentiation (LTP)213	Inhibition, NMDARs	leads to	Decreased, Calcium influx214	Inhibition, NMDARs	leads to	Impairment, Learning and memory215	Inhibition, NMDARs	leads to	N/A, Neuronal dysfunction228	Binding of antagonist, NMDA receptors	leads to	Impairment, Learning and memory229	Binding of antagonist, NMDA receptors	leads to	Inhibition, NMDARs235	Peptide Oxidation	leads to	N/A, Embryotoxicity236	Peptide Oxidation	leads to	Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)238	Peptide Oxidation	leads to	Increase, Pericardial edema239	N/A, Oxidative stress	leads to	N/A, Neuronal dysfunction240	Propagation, Oxidative stress	leads to	Down Regulation, Gulcose-6-phosphate dehydrogenase241	Propagation, Oxidative stress	leads to	"Damaging, Red blood cells; hemolysis"242	N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin	leads to	Altered regulation, Alpha hemoglobin243	N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin	leads to	Formation, Formation of hemoglobin adducts244	N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin	leads to	Propagation, Oxidative stress245	N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin	leads to	"Damaging, Red blood cells; hemolysis"248	Bile accumulation, Pathological condition	leads to	Activation of specific nuclear receptors, Transcriptional change252	Reduction, Plasma 17beta-estradiol concentrations	leads to	Reduction, Vitellogenin synthesis in liver253	Reduction, Plasma 17beta-estradiol concentrations	leads to	Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development254	Increase, Plasma vitellogenin concentrations	leads to	Increase, Renal pathology due to VTG deposition255	Reduction, Plasma vitellogenin concentrations	leads to	Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development256	demethylation, PPARg promoter	leads to	Decrease, Aromatase (Cyp19a1)257	Decreased, PPAR-alpha activation	leads to	Decreased, HSD17B10 expression259	Decreased, PPAR-beta activation	leads to	Decreased, HSD17B10 expression260	Decreased, PPAR-gamma activation	leads to	Decreased, HSD17B10 expression261	Induction, Pre-mature molting	leads to	Reduction, Fecundity262	Induction, Pre-mature molting	leads to	Increase, Mortality263	Induction, Pre-mature molting	leads to	Increased, Mortality264	Activation, Pregnane-X receptor, NR1l2	leads to	Up Regulation, Hepatic transporter gene expression265	Activation, Pregnane-X receptor, NR1l2	leads to	Induction, Upregulation of glucuronyltransferase activity266	Feminisation or incomplete development, Primary and accessory male sex organs	leads to	N/A, Impairment of reproductive capacity268	Reduction, Prostaglandin E2 concentration	leads to	N/A, Gap269	Alkylation, Protein	leads to	N/A, Cell injury/death271	Alkylation, Protein	leads to	Peptide Oxidation272	Increase, RBC congestion in liver	leads to	N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number276	Production, Reactive oxygen species	leads to	Peptide Oxidation277	"Damaging, Red blood cells; hemolysis"	leads to	Increase, Liver and splenic hemosiderosis278	"Damaging, Red blood cells; hemolysis"	leads to	N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number279	"Damaging, Red blood cells; hemolysis"	leads to	Increase, RBC congestion in liver280	Increase, Renal pathology due to VTG deposition	leads to	Altered, Larval development282	Increase, ROS production	leads to	Decreased, Nitric Oxide283	Increase, ROS production	leads to	Increased, Oxidative damage284	Activation, SCD-1	leads to	Synthesis, De Novo FA285	Decrease, Serum thyroxine (T4)	leads to	Decrease, Tissue thyroid hormone concentration287	Binding, SH-/selen-proteins	leads to	N/A, Interferences with SH-/selen-proteins294	Activation, SREBP-1c	leads to	Synthesis, De Novo FA295	Activation, Stellate cells	leads to	Accumulation, Collagen296	Increased, Structural malformations	leads to	Increased, Lethality297	Damage, Structure of the cochlea	leads to	Loss, Cochlear function298	Induction, Sustained Cell Proliferation	leads to	Formation, Liver tumor299	Induction, Sustained Hepatotoxicity	leads to	Induction, Sustained Cell Proliferation301	Activation/Proliferation, T-cells	leads to	N/A, Allergic contact dermatitis on challenge302	Reduction, Testosterone synthesis by ovarian theca cells	leads to	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells303	Up Regulation, TGFbeta1 expression	leads to	Accumulation, Collagen304	Up Regulation, TGFbeta1 expression	leads to	Activation, Stellate cells305	TH synthesis, Decreased	leads to	T4 in serum, Decreased309	Thyroperoxidase, Inhibition	leads to	TH synthesis, Decreased312	T4 in serum, Decreased	leads to	T4 in neuronal tissue, Decreased313	Decrease, Tissue thyroid hormone concentration	leads to	Decrease, TR-regulated cochlear proteins314	Decrease, TR-regulated cochlear proteins	leads to	Damage, Structure of the cochlea315	Reduction, Vitellogenin synthesis in liver	leads to	Reduction, Plasma vitellogenin concentrations316	Decreased, Transcription of genes by AR	leads to	Feminisation or incomplete development, Primary and accessory male sex organs317	Decreased, Transcription of genes by AR	leads to	Alteration, Wnt pathway319	Activation of specific nuclear receptors, Transcriptional change	leads to	Cholestasis, Pathology321	Accumulation, Triglyceride	leads to	Damaging, Mitochondria324	N/A, Unknown	leads to	Proliferation, Cell proliferation in the absence of cytotoxicity327	Induction, Upregulation of glucuronyltransferase activity	leads to	Up Regulation, Biliary excretion329	Insufficiency, Vascular	leads to	Abnormal, Morphogenesis330	Binding, VEGF-A	leads to	Decreased, VegfR2331	Binding, VEGF-A	leads to	Inhibition, VegfR2332	Production, VEGF-A	leads to	Binding, VEGF-A333	Production, VEGF-A	leads to	Decreased, VegfR2334	Decreased, VegfR2	leads to	Inhibition, VegfR2335	Inhibition, VegfR2	leads to	Reduction, Angiogenesis336	Increase, Vitellogenin synthesis in liver	leads to	Increase, Plasma vitellogenin concentrations337	Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development	leads to	Reduction, Cumulative fecundity and spawning338	Alteration, Wnt pathway	leads to	Feminisation or incomplete development, Primary and accessory male sex organs340	Activation, Pre-MIE: Metabolism of AFB1	leads to	Formation, Pro-mutagenic DNA Adducts342	Increased, Induced Mutations in Critical Genes	leads to	Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H343	Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H	leads to	Tumorigenesis, Hepatocellular carcinoma344	Formation, Pro-mutagenic DNA Adducts	leads to	Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H345	Formation, Pro-mutagenic DNA Adducts	leads to	Tumorigenesis, Hepatocellular carcinoma346	Increased, Induced Mutations in Critical Genes	leads to	Tumorigenesis, Hepatocellular carcinoma347	Decreased, Calcium influx	leads to	BDNF, Reduced348	BDNF, Reduced	leads to	Aberrant, Dendritic morphology350	Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci	leads to	Tumorigenesis, Hepatocellular carcinoma351	Increased, Induced Mutations in Critical Genes	leads to	Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci352	Formation, Pro-mutagenic DNA Adducts	leads to	Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci353	BDNF, Reduced	leads to	N/A, Cell injury/death354	BDNF, Reduced	leads to	Reduced, Presynaptic release of glutamate355	N/A, Cell injury/death	leads to	Synaptogenesis, Decreased 356	Aberrant, Dendritic morphology	leads to	Synaptogenesis, Decreased 357	Reduced, Presynaptic release of glutamate	leads to	Synaptogenesis, Decreased 358	Synaptogenesis, Decreased 	leads to	Neuronal network function, Decreased359	Neuronal network function, Decreased	leads to	Impairment, Learning and memory360	Binding of agonist, NMDARs	leads to	Overactivation, NMDARs361	Overactivation, NMDARs	leads to	Increased, Intracellular Calcium overload362	Increased, Intracellular Calcium overload	leads to	N/A, Mitochondrial dysfunction 1363	N/A, Mitochondrial dysfunction 1	leads to	N/A, Cell injury/death364	N/A, Cell injury/death	leads to	N/A, Neurodegeneration365	N/A, Cell injury/death	leads to	N/A, Neuroinflammation366	Thyroperoxidase, Inhibition	leads to	T4 in serum, Decreased368	N/A, Neurodegeneration	leads to	Neuronal network function, Decreased369	Activation, PPAR_	leads to	Decrease, Steroidogenic acute regulatory protein (STAR)370	Activation, PPAR_	leads to	Decrease, Translocator protein (TSPO)376	Covalent Binding, Protein	leads to	Response, Keratinocytes377	Covalent Binding, Protein	leads to	Activation, Dendritic Cells378	Response, Keratinocytes	leads to	Activation, Dendritic Cells379	Activation, Dendritic Cells	leads to	Activation/Proliferation, T-cells380	Response, Keratinocytes	leads to	Activation/Proliferation, T-cells381	Induction, Upregulation of glucuronyltransferase activity	leads to	Decrease, Serum thyroxine (T4)382	Increase, Biliary excretion TH glucuronide	leads to	Decrease, Serum thyroxine (T4)383	Thyroperoxidase, Inhibition	leads to	Cognitive Function, Decreased 384	Altered, Neurophysiology	leads to	Cognitive Function, Decreased 385	Activation, Glucocorticoid Receptor	leads to	Induction, IKB inhibitory protein386	Induction, IKB inhibitory protein	leads to	Inhibition, Nuclear factor kappa B (NF-kB)387	Inhibition, Nuclear factor kappa B (NF-kB)	leads to	Suppression, Inflammatory cytokines388	Suppression, Inflammatory cytokines	leads to	Decreased, Lymphocytes389	Decreased, Lymphocytes	leads to	Increased, Disease susceptibility390	Decreased, Lymphocytes	leads to	Suppression, Immune system392	Reduction, Plasma 17beta-estradiol concentrations	leads to	irregularities, ovarian cycle393	irregularities, ovarian cycle	leads to	Decrease, Fertility394	irregularities, ovarian cycle	leads to	impaired, Fertility395	demethylation, PPARg promoter	leads to	reduction in ovarian granulosa cells, Aromatase (Cyp19a1)396	reduction in ovarian granulosa cells, Aromatase (Cyp19a1)	leads to	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells398	Increase proliferation, Leydig cell 	leads to	Hyperplasia, Leydig cell399	Decrease, Translocator protein (TSPO)	leads to	Reduction, Testosterone synthesis in Leydig cells402	Metabolism of AFB1, Production of Reactive Electrophiles	leads to	Formation, Pro-mutagenic DNA Adducts403	T4 in serum, Decreased	leads to	Cognitive Function, Decreased 405	Malformation, Male reproductive tract	leads to	impaired, Fertility411	demethylation, PPARg promoter	leads to	Up Regulation, CD36428	Increased, Mortality	leads to	Decreased, Population trajectory432	Increased, Atrioventricular block and bradycardia	leads to	Increased, Mortality433	Increased, Respiratory distress/arrest	leads to	Increased, Mortality434	Induction, Ataxia, paralysis, or hyperactivity	leads to	Increased, Mortality436	Decrease, Steroidogenic acute regulatory protein (STAR)	leads to	Reduction, Cholesterol transport in mitochondria437	Decrease, Translocator protein (TSPO)	leads to	Reduction, Cholesterol transport in mitochondria438	Reduction, Cholesterol transport in mitochondria	leads to	Reduction, Testosterone synthesis in Leydig cells439	Reduction, Testosterone synthesis in Leydig cells	leads to	Reduction, testosterone level442	Inhibition, Na+/I- symporter (NIS)	leads to	Thyroidal Iodide, Decreased443	Thyroidal Iodide, Decreased	leads to	T4 in serum, Decreased444	T4 in neuronal tissue, Decreased	leads to	BDNF, Reduced445	BDNF, Reduced	leads to	Down Regulation, K-Cl co-transporter 2 (KCC2) 446	Down Regulation, K-Cl co-transporter 2 (KCC2) 	leads to	Delay, Developmental GABA shift 447	Delay, Developmental GABA shift 	leads to	Synaptogenesis, Decreased 448	BDNF, Reduced	leads to	Synaptogenesis, Decreased 449	Inhibition, Acetylcholinesterase (AchE)	leads to	Increased, Atrioventricular block and bradycardia450	Inhibition, Acetylcholinesterase (AchE)	leads to	Increased, Respiratory distress/arrest451	Inhibition, Acetylcholinesterase (AchE)	leads to	Induction, Ataxia, paralysis, or hyperactivity452	Inhibition, Acetylcholinesterase (AchE)	leads to	Increased, Mortality453	Inhibition, Acetylcholinesterase (AchE)	leads to	Decreased, Population trajectory454	Accumulation, Acetylcholine in synapses	leads to	Increased, Atrioventricular block and bradycardia456	Accumulation, Acetylcholine in synapses	leads to	Induction, Ataxia, paralysis, or hyperactivity457	Induction, Ataxia, paralysis, or hyperactivity	leads to	Increased, Respiratory distress/arrest459	Accumulation, Acetylcholine in synapses	leads to	Inhibition, Acetylcholinesterase (AchE)460	Reduction, testosterone level	leads to	Increase, Luteinizing hormone (LH) 461	Increase, Luteinizing hormone (LH) 	leads to	Increase proliferation, Leydig cell 462	Hyperplasia, Leydig cell	leads to	impaired, Fertility470	Inhibition, Mitochondrial fatty acid beta-oxidation	leads to	Accumulation, Liver lipid471	Suppression, VLDL secretion	leads to	Accumulation, Liver lipid472	Accumulation, Fatty acid	leads to	Accumulation, Triglyceride473	Activation, AhR	leads to	Inhibition, Mitochondrial fatty acid beta-oxidation474	Accumulation, Triglyceride	leads to	Accumulation, Liver lipid475	Inhibition, Mitochondrial fatty acid beta-oxidation	leads to	Accumulation, Fatty acid476	Suppression, Constitutive androstane receptor, NR1l3	leads to	Activation, LXR477	Suppression, Constitutive androstane receptor, NR1l3	leads to	demethylation, PPARg promoter478	Activation, LXR	leads to	Increased, Fatty acid uptake479	Activation, LXR	leads to	Activation, SREBF1481	Increased, Fatty acid uptake	leads to	Increased, Liver Steatosis482	Activation, SREBF1	leads to	Increased, De Novo FA synthesis483	Activation, ChREBP	leads to	Increased, De Novo FA synthesis484	Increased, De Novo FA synthesis	leads to	Increased, Triglyceride formation485	Increased, Fatty acid uptake	leads to	Increased, Triglyceride formation486	Increased, Triglyceride formation	leads to	Increased, Liver Steatosis487	demethylation, PPARg promoter	leads to	Activation, SREBF1488	demethylation, PPARg promoter	leads to	Increased, Fatty acid uptake489	Activation, SREBF1	leads to	Up Regulation, SCD-1490	Activation, LXR	leads to	Up Regulation, FAS491	Activation, LXR	leads to	Up Regulation, SCD-1492	Up Regulation, FAS	leads to	Increased, De Novo FA synthesis493	Up Regulation, SCD-1	leads to	Increased, Triglyceride formation494	Up Regulation, CD36	leads to	Increased, Fatty acid uptake495	Activation, AhR	leads to	Up Regulation, CD36496	Activation, AhR	leads to	Increased, FA Influx497	Activation, AhR	leads to	Increased, SCD-1499	Activation, AhR	leads to	Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)500	Increased, SCD-1	leads to	Accumulation, Triglyceride501	Up Regulation, CD36	leads to	Increased, FA Influx502	Accumulation, Fatty acid	leads to	Accumulation, Liver lipid503	Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)	leads to	Accumulation, Fatty acid504	Increased, FA Influx	leads to	Accumulation, Triglyceride505	Increased, FA Influx	leads to	Accumulation, Fatty acid506	Activation, AhR	leads to	Up Regulation, LDLR (low density lipoprotein receptor)507	Up Regulation, LDLR (low density lipoprotein receptor)	leads to	Increased, LDL uptake508	Increased, LDL uptake	leads to	Accumulation, Fatty acid509	Activation, AhR	leads to	Suppression, VLDL secretion510	Activation, LXR	leads to	Inhibition, PPAR alpha511	Inhibition, PPAR alpha	leads to	Inhibition, Mitochondrial fatty acid beta-oxidation512	Increased, De Novo FA synthesis	leads to	Accumulation, Fatty acid513	Increased, Fatty acid uptake	leads to	Accumulation, Fatty acid514	Accumulation, Fatty acid	leads to	Increased, Triglyceride formation515	Accumulation, Fatty acid	leads to	Increased, Liver Steatosis516	Activation, LXR	leads to	Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)517	Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)	leads to	Increased, De Novo FA synthesis518	Activation, PXR/SXR	leads to	Inhibition, FoxA2519	Inhibition, FoxA2	leads to	Down Regulation, CPT1A520	Down Regulation, CPT1A	leads to	Decreased, Mitochondrial fatty acid beta-oxidation521	Decreased, Mitochondrial fatty acid beta-oxidation	leads to	Accumulation, Hepatic FA522	Accumulation, Hepatic FA	leads to	Increased, Liver Steatosis523	Inhibition, FoxA2	leads to	Down Regulation, HMGCS2524	Down Regulation, HMGCS2	leads to	Decreased, Ketogenesis525	Decreased, Ketogenesis	leads to	Accumulation, Hepatic FA526	Activation, PXR/SXR	leads to	Up Regulation, SCD-1527	Up Regulation, SCD-1	leads to	Increased, Hepatic Triglycerides528	Increased, Hepatic Triglycerides	leads to	Increased, Liver Steatosis529	Activation, PXR/SXR	leads to	Up Regulation, CD36530	Increased, FA Influx	leads to	Increased, Hepatic Triglycerides531	Increased, FA Influx	leads to	Accumulation, Hepatic FA532	Activation, NRF2	leads to	Activation, NR1H4533	Activation, NR1H4	leads to	Activation, SHP534	Activation, NR1H4	leads to	Activation, PPAR_535	Activation, PPAR_	leads to	Activation, LXR alpha537	Decreased, DHB4/HSD17B4	leads to	Inhibition, Mitochondrial fatty acid beta-oxidation538	Inhibition, Mitochondrial fatty acid beta-oxidation	leads to	Increased, Liver Steatosis539	Activation, AKT2	leads to	Activtation, SREBP-1c540	Activtation, SREBP-1c	leads to	Increased, Liver Steatosis541	inflammation	leads to	Activation, AKT2544	Decrease, Ovulation	leads to	Reduction, Cumulative fecundity and spawning547	Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts	leads to	Increased, Induced Mutations in Critical Genes548	Formation, Pro-mutagenic DNA Adducts	leads to	Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts549	Increased, Induced Mutations in Critical Genes	leads to	Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)550	Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)	leads to	Tumorigenesis, Hepatocellular carcinoma551	Formation, Pro-mutagenic DNA Adducts	leads to	Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)552	Inhibition, Na+/I- symporter (NIS)	leads to	TH synthesis, Decreased558	Reduced, Food storage	leads to	Decrease, Number of worker bees559	Decrease, Number of worker bees	leads to	Death/Failure, Colony562	Reduced, Food storage	leads to	impaired, Larval development563	impaired, Larval development	leads to	Death/Failure, Colony564	Impairment, Learning and memory	leads to	Abnormal, Roll change within caste565	Abnormal, Roll change within caste	leads to	Reduced, Brood care566	Reduced, Brood care	leads to	impaired, Larval development567	Increase, Energetic demands and therefore metabolic stress	leads to	Increased, Appetite and hunger568	Increased, Appetite and hunger	leads to	Abnormal, Foraging activity and behavior569	Abnormal, Foraging activity and behavior	leads to	Decrease, Number of worker bees570	Suppression, Immune system	leads to	Increased, Viral susceptibility571	Increased, Viral susceptibility	leads to	impaired, Development572	impaired, Development	leads to	Decrease, Number of worker bees573	Decrease, Number of worker bees	leads to	impaired, Hive thermoregulation574	impaired, Hive thermoregulation	leads to	Death/Failure, Colony575	Increased, Viral susceptibility	leads to	Abnormal, Foraging activity and behavior576	Decreased, Glucose oxidase enzyme activity	leads to	Decreased, Hydrogen peroxide production577	Decreased, Hydrogen peroxide production	leads to	Reduced, Antiseptic incorporated in food578	Reduced, Antiseptic incorporated in food	leads to	Abnormal, Roll change within caste579	Abnormal, Roll change within caste	leads to	Reduced, Food storage580	Abnormal, Roll change within caste	leads to	Decrease, Number of worker bees581	Activation, Nicotinic acetylcholine receptor	leads to	N/A, Mitochondrial dysfunction 1582	N/A, Mitochondrial dysfunction 1	leads to	Neuronal network function, Decreased583	Impairment, Learning and memory	leads to	Abnormal, Foraging activity and behavior584	Abnormal, Foraging activity and behavior	leads to	Reduced, Food storage585	Inhibition, sodium channel	leads to	Decreased, Sodium conductance 1586	Decreased, Sodium conductance 1	leads to	Reduced, swimming speed587	Reduced, swimming speed	leads to	Reduced, feeding 1588	Reduced, swimming speed	leads to	Increased, predation589	Reduced, feeding 1	leads to	Increased, predation590	Inhibition, sodium channel	leads to	Increased, Atrioventricular block and bradycardia591	Increased, Atrioventricular block and bradycardia	leads to	Increased, Respiratory distress/arrest592	Increased, Respiratory distress/arrest	leads to	N/A, hypoxia593	N/A, hypoxia	leads to	Increased, amputations594	Decreased, Sodium conductance 1	leads to	Increased, Atrioventricular block and bradycardia595	Increased, predation	leads to	Reduced, survival596	Reduced, feeding 1	leads to	Reduced, survival597	Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel 	leads to	Decreased, Sodium conductance 1603	modulation, sodium channel	leads to	prolonged, Depolarization of neuronal membrane604	prolonged, Depolarization of neuronal membrane	leads to	Overactivation, Neuronotransmitter release605	Overactivation, Neuronotransmitter release	leads to	Overactivation, muscle contraction606	Overactivation, muscle contraction	leads to	Increased, Ataxia, paralysis, or hyperactivity607	Increased, Ataxia, paralysis, or hyperactivity	leads to	Increased, Mortality608	Reduction, testosterone level	leads to	Malformation, Male reproductive tract617	Decreased, Mitochondrial fatty acid beta-oxidation	leads to	Increased, Liver Steatosis630	Occurrence, A paroxysmal depolarizing shift	leads to	Occurrence, Epileptic seizure634	Decreased, Neuronal network function in adult brain	leads to	Impairment, Learning and memory635	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"	leads to	Increased, serotonin (5-HT) 1636	Increased, serotonin (5-HT) 1	leads to	Increase, cilia movement637	Increase, cilia movement	leads to	Increased, locomotion638	Increased, locomotion	leads to	Increase, predation639	Increase, cilia movement	leads to	Increased, foot detachment640	Increased, serotonin (5-HT) 1	leads to	Increased, muscular waves in foot641	Increased, muscular waves in foot	leads to	Increased, locomotion642	Increased, muscular waves in foot	leads to	Increased, foot detachment643	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"	leads to	Increased, serotonin (5-HT) 644	Increased, serotonin (5-HT) 	leads to	Decreased, anxiety645	Decreased, anxiety	leads to	Decreased, sheltering646	Decreased, sheltering	leads to	Increased, predation647	N/A, Neurodegeneration	leads to	Decreased, Neuronal network function in adult brain649	Decrease, histaminergic neuron excitation	leads to	N/A, sedation650	N/A, sedation	leads to	Decreased, locomotion651	Decreased, locomotion	leads to	Increased, predation654	Increased, predation	leads to	Decreased, survival656	Synaptogenesis, Decreased 	leads to	N/A, Neuroinflammation658	Activation, Nicotinic acetylcholine receptor	leads to	Desensitization, Nicotinic acetylcholine receptor659	Desensitization, Nicotinic acetylcholine receptor	leads to	Neuronal network function, Decreased660	N/A, Mitochondrial dysfunction 1	leads to	Overwhelmed, Mitochondrial DNA repair mechanisms661	Overwhelmed, Mitochondrial DNA repair mechanisms	leads to	Accumulation, Damaged mitochondrial DNA662	Accumulation, Damaged mitochondrial DNA	leads to	Accelerated, Aging663	Accelerated, Aging	leads to	Decrease, Number of worker bees664	N/A, Mitochondrial dysfunction 1	leads to	impaired, Thoracic shivering665	impaired, Thoracic shivering	leads to	impaired, Hive thermoregulation666	Binding at picrotoxin site, iGABAR chloride channel	leads to	Reduction, Ionotropic GABA receptor chloride channel conductance667	Reduction, Ionotropic GABA receptor chloride channel conductance	leads to	Reduction, Neuronal synaptic inhibition670	Inhibition, Cyclooxygenase activity	leads to	Reduced, Prostaglandin F2alpha synthesis, ovary 671	Reduced, Prostaglandin F2alpha synthesis, ovary 	leads to	Reduced, Prostaglandin F2alpha concentration, plasma 672	Reduced, Prostaglandin F2alpha concentration, plasma 	leads to	Reduced, Spawning behavior673	Reduced, Spawning behavior	leads to	Reduced, Ability to attract spawning mates674	Reduced, Ability to attract spawning mates	leads to	Reduced, Reproductive Success675	Reduced, Reproductive Success	leads to	Decrease, Population trajectory678	Reduced, Prostaglandin F2alpha concentration, plasma 	leads to	Reduced, Pheromone release679	Reduced, Pheromone release	leads to	Reduced, Ability to attract spawning mates680	Reduced, Reproductive Success	leads to	Decline, Population trajectory681	Inhibition, Cyclooxygenase activity	leads to	Decreased, Prostaglandin F2alpha synthesis, ovary 682	Decreased, Prostaglandin F2alpha synthesis, ovary 	leads to	Reduced, Prostaglandin F2alpha concentration, plasma 683	Reduction, Neuronal synaptic inhibition	leads to	Generation, Amplified excitatory postsynaptic potential (EPSP)684	Generation, Amplified excitatory postsynaptic potential (EPSP)	leads to	Occurrence, A paroxysmal depolarizing shift685	Reduced, Prostaglandins, ovary	leads to	Decrease, Ovulation686	Inhibition, Cyclooxygenase activity	leads to	Reduced, Prostaglandins, ovary687	Decrease, Ovulation	leads to	Reduced, Reproductive Success688	Reduced, Reproductive Success	leads to	Declining, Population trajectory689	Inhibition, Cyclooxygenase activity	leads to	Reduced, Prostaglandin E2 concentration, hypothalamus690	Reduced, Prostaglandin E2 concentration, hypothalamus	leads to	Reduced, Gonadotropin releasing hormone, hypothalamus691	Reduced, Gonadotropin releasing hormone, hypothalamus	leads to	Reduced, Luteinizing hormone (LH), plasma 692	Reduced, Luteinizing hormone (LH), plasma 	leads to	Reduced, Maturation inducing steroid, plasma693	Reduced, Maturation inducing steroid, plasma	leads to	Reduced, Maturation inducing steroid receptor signalling, oocyte694	Reduced, Maturation inducing steroid receptor signalling, oocyte	leads to	Increased, cyclic adenosine monophosphate695	Increased, cyclic adenosine monophosphate	leads to	Reduced, Reproductive Success696	Increased, cyclic adenosine monophosphate	leads to	Reduced, Meiotic prophase I/metaphase I transition, oocyte697	Reduced, Meiotic prophase I/metaphase I transition, oocyte	leads to	Reduced, Reproductive Success698	Reduced, Maturation inducing steroid receptor signalling, oocyte	leads to	Upregulated, Spindle assembly checkpoint protein Mad2-oocyte699	Upregulated, Spindle assembly checkpoint protein Mad2-oocyte	leads to	Increased, Chromosome misseggregation700	Increased, Chromosome misseggregation	leads to	Reduced, Reproductive Success701	impaired, ion channels	leads to	Altered, Action Potential702	Altered, Action Potential	leads to	Increased, cardiac arrthymia703	Increased, cardiac arrthymia	leads to	Increased, Mortality706	Increased, Binding of chemicals to 2u (serum)	leads to	Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium)707	Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium)	leads to	Increase, Cytotoxicity (renal tubular cell)708	Increase, Cytotoxicity (renal tubular cell)	leads to	Increase, Regenerative cell proliferation (tubular epithelial cells)711	Activation, Constitutive androstane receptor	leads to	Increase, Mitogenic cell proliferation (hepatocytes)714	Binding, Tubulin	leads to	Depolymerization, Microtubule715	Depolymerization, Microtubule	leads to	Disorganization, Spindle716	Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme	leads to	Increased, Induction of pyruvate dehydrogenase (PDH)723	Altered, Chromosome number	leads to	Increase, Aneuploid offspring724	Binding, Tubulin	leads to	Altered, Chromosome number726	Increase, Necrosis (terminal bronchiolar cells)	leads to	Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells)727	Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells)	leads to	Increase, Hyperplasia (terminal bronchiolar cells)728	Increase, Hyperplasia (terminal bronchiolar cells)	leads to	Increase, Adenomas/carcinomas (bronchioloalveolar)729	Decreased, Androgen receptor activity	leads to	Decreased, Testosterone binding to androgen receptor (hypothalamus)730	Decreased, Testosterone binding to androgen receptor (hypothalamus)	leads to	Increase, Hyperplasia (Leydig cells)731	Increase, Hyperplasia (Leydig cells)	leads to	Increase, Leydig cell tumors732	Increase, Dopaminergic activity	leads to	Decreased, Prolactin733	Decreased, Prolactin	leads to	Increased, Estrogen receptor (ER) activity734	Increased, Estrogen receptor (ER) activity	leads to	Decreased, Progesterone from corpus luteum737	Disorganization, Spindle	leads to	Altered, Meiotic chromosome dynamics738	Altered, Meiotic chromosome dynamics	leads to	Altered, Chromosome number741	Increase, Thyroid-stimulating hormone (TSH)	leads to	Increase, Hypertrophy and proliferation (follicular cell)742	Increase, Hypertrophy and proliferation (follicular cell)	leads to	Increase, Hyperplasia (follicular cells)743	Increase, Hyperplasia (follicular cells)	leads to	Increase, Adenomas/carcinomas (follicular cell)744	Decreased, Testosterone binding to androgen receptor (hypothalamus)	leads to	Increased, Luteinizing hormone (LH) 745	Increased, Luteinizing hormone (LH) 	leads to	Increase, Hyperplasia (Leydig cells)746	T4 in neuronal tissue, Decreased	leads to	Hippocampal gene expression, Altered 747	Hippocampal gene expression, Altered 	leads to	Hippocampal anatomy, Altered 748	Hippocampal Physiology, Altered	leads to	Cognitive Function, Decreased 749	Hippocampal anatomy, Altered 	leads to	Hippocampal Physiology, Altered750	Activation, 5HT2c	leads to	N/A, Unknown751	N/A, Unknown	leads to	Increased, Kidney Failure752	Activation, Glutamate-gated chloride channel	leads to	Increased, Chloride conductance755	hyperpolarisation, neuron	leads to	N/A, Ataxia, paralysis, or hyperactivity756	Increased, Mortality	leads to	Decreased, population 1757	N/A, Ataxia, paralysis, or hyperactivity	leads to	Increased, Mortality758	Increased, Chloride conductance	leads to	hyperpolarisation, neuron759	N/A, Neuroinflammation	leads to	Synaptogenesis, Decreased 760	Increase, Regenerative cell proliferation (tubular epithelial cells)	leads to	Increase, Hyperplasia (renal tubular cells)761	Increase, Hyperplasia (renal tubular cells)	leads to	Increase, Adenomas/carcinomas (renal tubular)762	Increased, Induction of pyruvate dehydrogenase (PDH)	leads to	Increase, Oxidative metabolism763	Increase, Oxidative metabolism	leads to	Peptide Oxidation764	Peptide Oxidation	leads to	Increase, Adenomas/carcinomas (hepatocellular)765	Peptide Oxidation	leads to	Increase, Cytotoxicity766	Increase, Cytotoxicity	leads to	Increase, Adenomas/carcinomas (hepatocellular)767	Increase, Cytotoxicity (club cells)	leads to	Increase, Necrosis (terminal bronchiolar cells)768	Decreased, Uptake of inorganic iodide	leads to	Decrease, Serum thyroid hormone (T4/T3)769	Decrease, Serum thyroid hormone (T4/T3)	leads to	Increase, Thyroid-stimulating hormone (TSH)770	Increase, Dopaminergic activity	leads to	Increase, Endometrial adenocarcinomas771	Increase, Hyperplasia (glandular epithelial cells of endometrium)	leads to	Increase, Endometrial adenocarcinomas772	Decreased, Progesterone from corpus luteum	leads to	Increase, Hyperplasia (glandular epithelial cells of endometrium)773	Increase, Mitogenic cell proliferation (hepatocytes)	leads to	Increase, Preneoplastic foci (hepatocytes)774	Increase, Preneoplastic foci (hepatocytes)	leads to	Increase, Adenomas/carcinomas (hepatocellular)775	Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme	leads to	Increased, Plasma tyrosine776	Increased, Plasma tyrosine	leads to	Increase, Cytotoxicity (corneal cells)777	Increase, Cytotoxicity (corneal cells)	leads to	Increase, Inflammation (corneal cells)778	Increase, Inflammation (corneal cells)	leads to	Increase, Regenerative cell proliferation (corneal cells)779	Increase, Regenerative cell proliferation (corneal cells)	leads to	Increase, Papillomas/carcinomas (squamous cells)780	Increase, Cytotoxicity (epithelial cells)	leads to	Increase, Inflammation781	Increase, Inflammation	leads to	Increase, Regenerative cell proliferation (forestomach epithelial cells)782	Increase, Regenerative cell proliferation (forestomach epithelial cells)	leads to	Increase, Hyperplasia (forestomach epithelial cells)783	Increase, Hyperplasia (forestomach epithelial cells)	leads to	Increase, Papillomas/carcinomas (squamous cells)784	Increase, Cytotoxicity (tubular epithelial cells)	leads to	Increase, Regenerative cell proliferation (tubular epithelial cells)785	Increase, Regenerative cell proliferation (tubular epithelial cells)	leads to	Increase, Hyperplasia (tubular epithelial cells)786	Increase, Hyperplasia (tubular epithelial cells)	leads to	Increase, Adenomas/carcinomas (renal tubular)787	Activation, Androgen receptor	leads to	Increase, Mitogenic cell proliferation (hepatocytes)788	Increase, Cytotoxicity (hepatocytes)	leads to	Increase, Regenerative cell proliferation (hepatocytes)789	Increase, Regenerative cell proliferation (hepatocytes)	leads to	Increase, Preneoplastic foci (hepatocytes)790	Thyroperoxidase, Inhibition	leads to	Decrease, Incorporation of active iodide into iodotyrosines791	Decrease, Incorporation of active iodide into iodotyrosines	leads to	Decrease, Serum thyroid hormone (T4/T3)792	Inhibition, 5_-reductase activity	leads to	Decrease, Bioactivation of testosterone793	Decrease, Bioactivation of testosterone	leads to	Increased, Leutinizing hormone (LH)794	Increased, Leutinizing hormone (LH)	leads to	Increase, Hyperplasia (Leydig cells)795	Increase, Urinary bladder calculi	leads to	Increase, Cytotoxicity (urothelial cells)796	Increase, Cytotoxicity (urothelial cells)	leads to	Increase, Regenerative cell proliferation (urothelial cells)797	Increase, Regenerative cell proliferation (urothelial cells)	leads to	Increase, Hyperplasia (urothelial)798	Increase, Hyperplasia (urothelial)	leads to	Increase, Adenomas/carcinomas (urothelial)799	Inhibition, Prolyl hydroxylases	leads to	Increased, HIF-1 heterodimer800	Increased, HIF-1 heterodimer	leads to	Decreased, Aromatase (Cyp19a1) mRNA801	Decreased, Aromatase (Cyp19a1) mRNA	leads to	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells802	modulation, Unknown	leads to	Increased, HIF-1 alpha transcription803	Increased, HIF-1 alpha transcription	leads to	Increased, HIF-1 heterodimer804	Inhibition, HMG-CoA reductase	leads to	Decreased, mevalonate805	Decreased, mevalonate	leads to	Decreased, cholesterol806	Decreased, cholesterol	leads to	Decreased, Testosterone807	Decreased, Testosterone	leads to	malformed, Male reproductive tract808	malformed, Male reproductive tract	leads to	Decrease, Fertility809	TH synthesis, Decreased	leads to	Decreased, Thyroxine (T4) in serum810	TH synthesis, Decreased	leads to	Increased, Serum creatinine811	Decreased, Thyroxine (T4) in serum	leads to	Occurrence, Cytoplasmic vacuolization (Renal tubule)812	Decreased, Thyroxine (T4) in serum	leads to	Occurrence, Cystic dilatation (renal tubule)813	Increased, Serum creatinine	leads to	Occurrence, Cytoplasmic vacuolization (Renal tubule)814	Increased, Serum creatinine	leads to	Occurrence, Cystic dilatation (renal tubule)815	Decreased, Thyroxine (T4) in serum	leads to	Occurrence, Cytoplasmic vacuolization (podocyte)816	Increased, Serum creatinine	leads to	Occurrence, Cytoplasmic vacuolization (podocyte)817	Occurrence, Cytoplasmic vacuolization (Renal tubule)	leads to	Decreased, Glomerular filtration818	Occurrence, Cytoplasmic vacuolization (Renal tubule)	leads to	Decreased, Renal plasma flow819	Occurrence, Cytoplasmic vacuolization (Renal tubule)	leads to	Decreased, Sodium reabsorption820	Occurrence, Cytoplasmic vacuolization (Renal tubule)	leads to	Decreased, Renal ability to dilute urine821	Occurrence, Cystic dilatation (renal tubule)	leads to	Decreased, Glomerular filtration822	Occurrence, Cystic dilatation (renal tubule)	leads to	Decreased, Renal plasma flow823	Occurrence, Cystic dilatation (renal tubule)	leads to	Decreased, Sodium reabsorption824	Occurrence, Cystic dilatation (renal tubule)	leads to	Decreased, Renal ability to dilute urine825	Occurrence, Cytoplasmic vacuolization (podocyte)	leads to	Decreased, Glomerular filtration826	Occurrence, Cytoplasmic vacuolization (podocyte)	leads to	Decreased, Renal plasma flow827	Occurrence, Cytoplasmic vacuolization (podocyte)	leads to	Decreased, Sodium reabsorption828	Occurrence, Cytoplasmic vacuolization (podocyte)	leads to	Decreased, Renal ability to dilute urine829	Decreased, Glomerular filtration	leads to	Occurrence, Kidney toxicity830	Decreased, Renal plasma flow	leads to	Occurrence, Kidney toxicity831	Decreased, Sodium reabsorption	leads to	Occurrence, Kidney toxicity832	Decreased, Renal ability to dilute urine	leads to	Occurrence, Kidney toxicity833	Covalent Binding, Protein	leads to	Activation, Keratinocytes834	Activation, Keratinocytes	leads to	Activation, Dendritic Cells835	Activation/Proliferation, T-cells	leads to	sensitisation, skin836	Inhibition, Phospholipase A	leads to	Damage, Lipid bilayer837	Inhibition, Phospholipase A	leads to	Disturbance, Lysosomal function838	Inhibition, Phospholipase A	leads to	Injury, Mitochondria839	Damage, Lipid bilayer	leads to	Occurrence, Cytoplasmic vacuolization (hepatocyte)840	Damage, Lipid bilayer	leads to	Occurrence, Ballooning degeneration (hepatocyte)841	Damage, Lipid bilayer	leads to	Occurrence, Cytoplasmic vacuolization (Bile duct cell)842	Damage, Lipid bilayer	leads to	Occurrence, Cytoplasmic vacuolization (kupffer cell)843	Disturbance, Lysosomal function	leads to	Occurrence, Cytoplasmic vacuolization (hepatocyte)844	Disturbance, Lysosomal function	leads to	Occurrence, Ballooning degeneration (hepatocyte)845	Disturbance, Lysosomal function	leads to	Occurrence, Cytoplasmic vacuolization (Bile duct cell)846	Disturbance, Lysosomal function	leads to	Occurrence, Cytoplasmic vacuolization (kupffer cell)847	Injury, Mitochondria	leads to	Occurrence, Cytoplasmic vacuolization (hepatocyte)848	Injury, Mitochondria	leads to	Occurrence, Ballooning degeneration (hepatocyte)849	Injury, Mitochondria	leads to	Occurrence, Cytoplasmic vacuolization (Bile duct cell)850	Injury, Mitochondria	leads to	Occurrence, Cytoplasmic vacuolization (kupffer cell)851	Occurrence, Cytoplasmic vacuolization (hepatocyte)	leads to	Induction, Microvesicular fat852	Occurrence, Cytoplasmic vacuolization (hepatocyte)	leads to	Formation, Mallory body853	Occurrence, Ballooning degeneration (hepatocyte)	leads to	Induction, Microvesicular fat854	Occurrence, Ballooning degeneration (hepatocyte)	leads to	Formation, Mallory body855	Occurrence, Cytoplasmic vacuolization (Bile duct cell)	leads to	Induction, Microvesicular fat856	Occurrence, Cytoplasmic vacuolization (Bile duct cell)	leads to	Formation, Mallory body857	Occurrence, Cytoplasmic vacuolization (kupffer cell)	leads to	Induction, Microvesicular fat858	Occurrence, Cytoplasmic vacuolization (kupffer cell)	leads to	Formation, Mallory body859	Induction, Microvesicular fat	leads to	Formation, Liver fibrosis860	Formation, Mallory body	leads to	Formation, Liver fibrosis864	Oxidation, Uroporphyrinogen	leads to	Accumulation, Highly carboxylated porphyrins865	Oxidation, Uroporphyrinogen	leads to	Inhibition, UROD866	Accumulation, Highly carboxylated porphyrins	leads to	Uroporphyria867	Inhibition, UROD	leads to	Oxidation, Uroporphyrinogen868	Induction, CYP1A2/CYP1A5	leads to	Oxidation, Uroporphyrinogen869	Activation, AhR	leads to	Induction, CYP1A2/CYP1A5870	BDNF, Reduced	leads to	GABAergic interneurons, Decreased871	GABAergic interneurons, Decreased	leads to	Synaptogenesis, Decreased 872	Thyroidal Iodide, Decreased	leads to	TH synthesis, Decreased874	Activation, Long term AHR receptor driven direct and indirect gene expression changes	leads to	Changes/Inhibition, Cellular Homeostasis and Apoptosis875	Activation, Long term AHR receptor driven direct and indirect gene expression changes	leads to	Alterations, Cellular proliferation / hyperplasia876	Activation, Long term AHR receptor driven direct and indirect gene expression changes	leads to	Formation, Hepatocellular and Bile duct tumors877	Binding as antagonist, Antagonist binding to PPARalpha ligand binding domain	leads to	Decreased, PPARalpha transactivation of gene expression878	Decreased, PPARalpha transactivation of gene expression	leads to	Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids879	Decreased, PPARalpha transactivation of gene expression	leads to	Decreased, Mitochondrial Fatty Acid Beta Oxidation880	Decreased, PPARalpha transactivation of gene expression	leads to	Decreased, Ketogenesis (production of ketone bodies)881	Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids	leads to	Decreased, Mitochondrial Fatty Acid Beta Oxidation882	Decreased, Mitochondrial Fatty Acid Beta Oxidation	leads to	Decreased, Ketogenesis (production of ketone bodies)883	Decreased, Ketogenesis (production of ketone bodies)	leads to	Not Increased, Circulating Ketone Bodies884	Not Increased, Circulating Ketone Bodies	leads to	Increased, Catabolism of Muscle Protein885	Increased, Catabolism of Muscle Protein	leads to	Decreased, Body Weight886	Decrease, Intracellular pH	leads to	Increase, Cytotoxicity887	Increase, Cytotoxicity	leads to	Increase, Tissue Degeneration, Necrosis & Atrophy 888	Increase, Tissue Degeneration, Necrosis & Atrophy 	leads to	Increase, Respiratory or Squamous Metaplasia889	Increase, Respiratory or Squamous Metaplasia	leads to	Increase, Cell Proliferation890	Increase, Cell Proliferation	leads to	Increased, Induced Mutations in Critical Genes891	Increased, Induced Mutations in Critical Genes	leads to	Increase, Site of Contact Nasal Tumors892	Increased, Intracellular Calcium overload	leads to	Decreased, Neuronal network function in adult brain893	Increase, Cell Proliferation	leads to	Increase, Mutations in Critical Genes894	Increase, Mutations in Critical Genes	leads to	Increase, Site of Contact Nasal Tumors895	Increase, Cell Proliferation	leads to	Increase, Site of Contact Nasal Tumors896	Activation, SHP	leads to	Inhibition, SREBP1c899	Increase, Mutations	leads to	Increase, Cancer901	Alkylation, DNA	leads to	Increase, Cancer904	N/A, Mitochondrial dysfunction 1	leads to	Impaired, Proteostasis905	Impaired, Proteostasis	leads to	Degeneration of dopaminergic neurons of the nigrostriatal pathway906	N/A, Neuroinflammation	leads to	Degeneration of dopaminergic neurons of the nigrostriatal pathway907	Degeneration of dopaminergic neurons of the nigrostriatal pathway	leads to	N/A, Neuroinflammation908	N/A, Mitochondrial dysfunction 1	leads to	Degeneration of dopaminergic neurons of the nigrostriatal pathway910	Degeneration of dopaminergic neurons of the nigrostriatal pathway	leads to	Parkinsonian motor deficits911	Disruption, Lysosome	leads to	Increase, ROS production912	Increase, ROS production	leads to	N/A, Mitochondrial dysfunction 1916	Infiltration, Inflammatory cells	leads to	Inflammation, Liver919	Binding of agonist, Ionotropic glutamate receptors	leads to	Overactivation, NMDARs921	Disruption, Lysosome	leads to	Peptide Oxidation922	Peptide Oxidation	leads to	N/A, Mitochondrial dysfunction 1923	Peptide Oxidation	leads to	Release, Cytokine924	N/A, Cell injury/death	leads to	Release, Cytokine925	Release, Cytokine	leads to	Infiltration, Inflammatory cytokines926	Infiltration, Inflammatory cytokines	leads to	Inflammation, Liver927	Inhibition, Bile Salt Export Pump (ABCB11)	leads to	Bile accumulation, Pathological condition928	Bile accumulation, Pathological condition	leads to	Release, Cytokine929	Increase, Inflammation	leads to	Cholestasis, Pathology930	Bile accumulation, Pathological condition	leads to	Production, Reactive oxygen species931	Production, Reactive oxygen species	leads to	Cholestasis, Pathology932	Peptide Oxidation	leads to	Cholestasis, Pathology933	Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I)	leads to	Inhibition, NADH-ubiquinone oxidoreductase (complex I)934	Inhibition, NADH-ubiquinone oxidoreductase (complex I)	leads to	N/A, Mitochondrial dysfunction 1936	Activation, Epidermal Growth Factor Receptor	leads to	Decrease, Apoptosis of ciliated epithelial cells939	Activation, Epidermal Growth Factor Receptor	leads to	Increase, Proliferation of goblet cells942	Activation, Epidermal Growth Factor Receptor	leads to	Occurrence, Transdifferentiation of ciliated epithelial cells943	Occurrence, Transdifferentiation of ciliated epithelial cells	leads to	Occurrence, Metaplasia of goblet cells944	Increase, Proliferation of goblet cells	leads to	Goblet cell hyperplasia946	Activation, Epidermal Growth Factor Receptor	leads to	Activation, SP1948	Peptide Oxidation	leads to	Oxidation, Glutathione952	Decrease, GTPCH-1	leads to	Decrease, Tetrahydrobiopterin953	Decrease, Tetrahydrobiopterin	leads to	Uncoupling, eNOS954	Oxidation, Glutathione	leads to	S-Glutathionylation, eNOS955	S-Glutathionylation, eNOS	leads to	Uncoupling, eNOS956	Uncoupling, eNOS	leads to	Depletion, Nitric Oxide958	Depletion, Nitric Oxide	leads to	impaired, Vasodilation961	Decrease, Apoptosis of ciliated epithelial cells	leads to	Occurrence, Transdifferentiation of ciliated epithelial cells962	Activation, EGFR	leads to	Decrease, Apoptosis of ciliated epithelial cells964	Activation, EGFR	leads to	Activation, SP1965	Activation, EGFR	leads to	Occurrence, Transdifferentiation of ciliated epithelial cells970	Activation, EGFR	leads to	Increase, Proliferation of goblet cells972	Activation, AhR	leads to	dimerization, AHR/ARNT973	dimerization, AHR/ARNT	leads to	reduced dimerization, ARNT/HIF1-alpha974	reduced dimerization, ARNT/HIF1-alpha	leads to	reduced production, VEGF975	reduced production, VEGF	leads to	Impairment, Endothelial network976	Impairment, Endothelial network	leads to	Altered, Cardiovascular development/function977	Altered, Cardiovascular development/function	leads to	Increase, Pericardial edema978	Increase, Pericardial edema	leads to	Increase, Embryolethality980	Peptide Oxidation	leads to	Decrease, GTPCH-1982	impaired, Vasodilation	leads to	Increase, Vascular Resistance983	Increase, Vascular Resistance	leads to	Hypertension984	Activation, AhR	leads to	Increase, Embryolethality986	Activation, EGFR	leads to	Increase, Mucin production987	Activation, SP1	leads to	Increase, Mucin production988	Decrease, Akt/eNOS activity	leads to	Depletion, Nitric Oxide989	Goblet cell hyperplasia	leads to	Hypersecretion, Mucus990	Occurrence, Metaplasia of goblet cells	leads to	Hypersecretion, Mucus991	Increase, Mucin production	leads to	Hypersecretion, Mucus992	Peptide Oxidation	leads to	Decrease, Akt/eNOS activity993	Disruption, Lysosome	leads to	N/A, Mitochondrial dysfunction 1994	Release, Cytokine	leads to	Infiltration, Inflammatory cells995	Changes/Inhibition, Cellular Homeostasis and Apoptosis	leads to	N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects996	N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects	leads to	Alterations, Cellular proliferation / hyperplasia997	Alterations, Cellular proliferation / hyperplasia	leads to	Formation, Hepatocellular and Bile duct tumors998	Activation, EcR	leads to	Reduction, Release of circulating ETH999	Activation, EcR	leads to	Decreased, synthesis and secretion of molting fluid proteases1000	Reduction, Release of circulating ETH	leads to	Induction, Incomplete ecdysis1001	Decreased, synthesis and secretion of molting fluid proteases	leads to	Induction, Incomplete ecdysis1002	Induction, Incomplete ecdysis	leads to	Increase, Mortality1003	Decline, Population	leads to	Increased, Alterations of food-web structures1004	Increase, Mortality	leads to	Decreased, population 11005	Decreased, population 1	leads to	Increased, Alterations of food-web structures1006	Decline, Population	leads to	Alterations, Food-web structures1007	Activation, EcR	leads to	Decreased, Synthesis of molting fluid proteases1008	Reduction, Release of circulating ETH	leads to	Reduction, Abdominal muscle contraction1009	Decreased, Synthesis of molting fluid proteases	leads to	Decreased, Digestion of old cuticle1010	Reduction, Abdominal muscle contraction	leads to	Induction, Incomplete ecdysis1011	Decreased, Digestion of old cuticle	leads to	Induction, Incomplete ecdysis1012	Decreased, Population size	leads to	Alterations, Food-web structures1013	Increase, Mortality	leads to	Decreased, Population size1015	Inhibition, Calcineurin Activity	leads to	Activation, Suppression of NFAT activation and hindrance of nuclear localization1016	Activation, Suppression of NFAT activation and hindrance of nuclear localization	leads to	Interference, nuclear localization of NFAT1017	Interference, nuclear localization of NFAT	leads to	Reduction, NFAT complex formation1018	Reduction, NFAT complex formation	leads to	Suppression, Suppression in mixed lymphocyte reaction (MLR)1019	Reduction, NFAT complex formation	leads to	Suppression, Suppression of T-cell dependent antibody response (TDAR) 1020	Reduction, NFAT complex formation	leads to	Impairment, T-cell dependent antibody response1021	Reduction, NFAT complex formation	leads to	Relief, Relief of atopic dermatitis1022	Reduction, NFAT complex formation	leads to	Increase, Increased susceptibility to infection1023	Binding of antagonist, PPAR alpha	leads to	stabilization, PPAR alpha co-repressor1024	stabilization, PPAR alpha co-repressor	leads to	Decreased, PPARalpha transactivation of gene expression1025	Abnormal, Morphogenesis	leads to	Increased, Developmental Defects1026	Inhibition, Deiodinase 2	leads to	Decreased, Triiodothyronine (T3) in serum1027	Decreased, Triiodothyronine (T3) in serum	leads to	Reduced, Posterior swim bladder inflation1028	Reduced, Posterior swim bladder inflation	leads to	Reduced, Swimming performance1029	Reduced, Swimming performance	leads to	Reduced, Young of year survival1030	Reduced, Young of year survival	leads to	Decrease, Population trajectory1031	Reduced, Posterior swim bladder inflation	leads to	Reduced, Anterior swim bladder inflation1032	Reduced, Anterior swim bladder inflation	leads to	Reduced, Hearing1033	Reduced, Hearing	leads to	Reduced, Young of year survival1034	Reduced, Anterior swim bladder inflation	leads to	Reduced, Swimming performance1035	Decreased, Triiodothyronine (T3) in serum	leads to	Reduced, Anterior swim bladder inflation1036	Insufficiency, Vascular	leads to	Increased, Developmental Defects1037	Inhibition, Deiodinase 1	leads to	Decreased, Triiodothyronine (T3) in serum1039	T4 in serum, Decreased	leads to	Reduced, Anterior swim bladder inflation1040	Thyroperoxidase, Inhibition	leads to	Reduced, Anterior swim bladder inflation1041	Reduced, Posterior swim bladder inflation	leads to	Reduced, Young of year survival1042	Inhibition, Deiodinase 2	leads to	Reduced, Posterior swim bladder inflation1043	Inhibition, Deiodinase 2	leads to	Reduced, Anterior swim bladder inflation1044	Inhibition, Deiodinase 1	leads to	Reduced, Posterior swim bladder inflation1045	Inhibition, Deiodinase 1	leads to	Reduced, Anterior swim bladder inflation1047	Increased, Chloride influx	leads to	Increased, Inhibitory postsynaptic potential1048	Increased, Inhibitory postsynaptic potential	leads to	Inhibition, Motor neuron activity1049	Inhibition, Motor neuron activity	leads to	Induction, Somatic muscle paralysis1050	Induction, Somatic muscle paralysis	leads to	Increased, Mortality1051	Activation, ionotropic GABA Receptor chloride channel	leads to	Increased, Chloride conductance1052	Increased, Chloride conductance	leads to	Increased, Neuronal synaptic inhibition1053	Increased, Neuronal synaptic inhibition	leads to	Increased, Inhibitory postsynaptic potential1054	Increased, Inhibitory postsynaptic potential	leads to	Induction, Somatic muscle paralysis1055	Induction, Somatic muscle paralysis	leads to	Inhibition, Feeding1056	Inhibition, Feeding	leads to	Increased, Mortality1057	Activation, Glutamate-gated chloride channels	leads to	Increased, Chloride conductance1058	Increased, Inhibitory postsynaptic potential	leads to	Induction, pharyngeal muscle paralysis1059	Induction, pharyngeal muscle paralysis	leads to	Inhibition, Feeding1060	Induction, Upregulation of glucuronyltransferase activity	leads to	Increase, Biliary excretion TH glucuronide1061	Antagonism, Histamine Receptor (H2)	leads to	Decrease, histaminergic neuron excitation1062	Formation, The binding of FK506 with FKBP12	leads to	Inhibition, Calcineurin Activity1063	Increased, induction of UDPGT's in liver	leads to	Increased, T4/T3 catabolism1064	Increased, T4/T3 catabolism	leads to	Decreased, serum T4/T31065	Decreased, serum T4/T3	leads to	Increased, Thyroid-stimulating hormone (TSH)1066	Increased, Thyroid-stimulating hormone (TSH)	leads to	Increased, Hypertrophy and proliferation (follicular cell)1067	Increased, Hypertrophy and proliferation (follicular cell)	leads to	Increased, Hyperplasia (follicular cells)1068	Increased, Hyperplasia (follicular cells)	leads to	Increased Apoptosis, Adenomas/carcinomas (follicular cell)1069	N/A, Neurodegeneration	leads to	Impairment, Learning and memory1070	Inhibition, UROD	leads to	Accumulation, Highly carboxylated porphyrins1071	Activation of specific nuclear receptors, PPAR-gamma activation	leads to	Increased, adipogenesis1072	Activation of specific nuclear receptors, PPAR-gamma activation	leads to	Increased, secretion of local growth factors1073	Increased, adipogenesis	leads to	Increased, secretion of local growth factors1074	Increased, secretion of local growth factors	leads to	Increased, proliferation of mesenchymal cells1075	Increased, secretion of local growth factors	leads to	Increased, IGF-1 (mouse)1076	Increased, proliferation of mesenchymal cells	leads to	Increased, Firbrosarcoma1077	Increased, proliferation of mesenchymal cells	leads to	Increased, liposarcoma1078	Increased, proliferation of mesenchymal cells	leads to	Increased, hemagiosarcoma1079	Activation, beta-2 adrenergic receptor	leads to	Increased activity, beta-2 adrenergic receptor1080	Increased activity, beta-2 adrenergic receptor	leads to	relaxation, smooth muscle1081	relaxation, smooth muscle	leads to	Proliferation/Clonal Expansion, smooth muscle1082	Proliferation/Clonal Expansion, smooth muscle	leads to	Hypertrophy/hyperplasia, smooth muscle1083	Hypertrophy/hyperplasia, smooth muscle	leads to	Promotion, mesovarian leiomyomas1084	Decreased, Ovarian E2	leads to	Increased, secretion of GnRH from hypothalamus1085	Decreased, Ovarian E2	leads to	Decrease, E2 blood concentrations at hypothalamus1086	Suppression, Estrogen receptor (ER) activity	leads to	Decrease, E2 blood concentrations at hypothalamus1087	Decrease, E2 blood concentrations at hypothalamus	leads to	Increased, secretion of GnRH from hypothalamus1088	Increased, secretion of GnRH from hypothalamus	leads to	Increased, secrection of FSH from anterior pituitary1089	Increased, secretion of GnRH from hypothalamus	leads to	Increased, secretion of LH from anterior pituitary1090	Increased, secrection of FSH from anterior pituitary	leads to	Hyperplasia, ovarian stromal cells1091	Increased, secrection of FSH from anterior pituitary	leads to	Hyperplasia, ovarian epithelium1092	Increased, secretion of LH from anterior pituitary	leads to	Hyperplasia, ovarian stromal cells1093	Hyperplasia, ovarian epithelium	leads to	Promotion, ovarian adenomas1094	Hyperplasia, ovarian stromal cells	leads to	Promotion, ovarian granular cell tumors1095	Increased, PPAR-alpha activation	leads to	Decreased, bile flow1096	Increased, PPAR-alpha activation	leads to	Increased, cholestasis1097	Increased, PPAR-alpha activation	leads to	Alteration, lipid metabolism1098	prolonged, elevation of serun CCK	leads to	Increased, Cellular proliferation / hyperplasia of acinar cells1099	Increased, Cellular proliferation / hyperplasia of acinar cells	leads to	Increased, Pancreatic acinar tumors1100	Increased, cholestasis	leads to	prolonged, elevation of serun CCK1101	Decreased, bile flow	leads to	Increased, cholestasis1102	prepubertal increase, Estrogen receptor (ER) activity	leads to	Activation, estrogen receptor alpha1103	Activation, estrogen receptor alpha	leads to	Promotion, SIX-1 postive basal-type progenitor cells1104	Promotion, SIX-1 postive basal-type progenitor cells	leads to	Proliferation/Clonal Expansion, aberrant basal cells1105	Proliferation/Clonal Expansion, aberrant basal cells	leads to	squamous metaplasia, aberrant basal cells1106	squamous metaplasia, aberrant basal cells	leads to	Increased, Hyperplasia (glandular epithelial cells of endometrium)1107	Increased, Hyperplasia (glandular epithelial cells of endometrium)	leads to	Increased, adenosquamous carcinomas of endometrium1108	Decreased, GnRH pulsatility/release in hypothalamus	leads to	Decreased, LH Surge from anterior pituitary1109	Decreased, LH Surge from anterior pituitary	leads to	interruption, Ovulation1110	Decreased, LH Surge from anterior pituitary	leads to	prolonged, estrus1111	prolonged, estrus	leads to	Increased, circulating estrogen levels1112	prolonged, estrus	leads to	Increased, prolactin exposure1113	Increased, circulating estrogen levels	leads to	Hyperplasia, Mammary gland1114	Increased, prolactin exposure	leads to	Hyperplasia, Mammary gland1115	Hyperplasia, Mammary gland	leads to	Increased, latency period1116	Hyperplasia, Mammary gland	leads to	Increased, Adenomas/carcinomas (mammary)1117	Increased, latency period	leads to	Increased, Adenomas/carcinomas (mammary)1118	interruption, Ovulation	leads to	Increased, circulating estrogen levels1119	Increased, circulating estrogen levels	leads to	Increased, lactotroph hyperplasia and hypertrophy1120	Increased, lactotroph hyperplasia and hypertrophy	leads to	Increased, adenomas (pituitary)1121	Decreased, Dopaminergic activity	leads to	Increased, prolactin secretion1122	Increased, prolactin secretion	leads to	Increased, hyperplasia (mammary gland)1123	Increased, hyperplasia (mammary gland)	leads to	Increased, latency period1124	Increased, hyperplasia (mammary gland)	leads to	Increased, Adenomas/carcinomas (mammary)1125	persistent, cytotoxicity (pleura or peritoneum)	leads to	Increased, inflammation1126	persistent, cytotoxicity (pleura or peritoneum)	leads to	Increased, Oxidative Stress1127	Increased, inflammation	leads to	Increased, secretion of local growth factors1128	Increased, Oxidative Stress	leads to	Increased, secretion of local growth factors1129	Increased, secretion of local growth factors	leads to	Increased, Cell Proliferation (mesothelium)1130	Increased, Cell Proliferation (mesothelium)	leads to	Increased, mesotheliomas1131	Inhibition, organic anion transporter 1 (OAT1)	leads to	Increased, blood uric acid concentration1132	Increased, blood uric acid concentration	leads to	Occurrence, tophi (urate) deposition1133	Occurrence, tophi (urate) deposition	leads to	Occurrence, renal proximal tubular necrosis1134	Occurrence, renal proximal tubular necrosis	leads to	Increased, blood potassium concentration1135	Increased, blood potassium concentration	leads to	Occurrence, cardiac arrthymia1136	Occurrence, cardiac arrthymia	leads to	Increased, Mortality1137	Inhibition, Cyclooxygenase 1 activity	leads to	Decreased, Prostaglandin F2alpha concentration, plasma 1138	Decreased, Prostaglandin F2alpha concentration, plasma 	leads to	Occurrence, renal ischemia1139	Occurrence, renal ischemia	leads to	Occurrence, renal proximal tubular necrosis1140	Increased, blood potassium concentration	leads to	Occurrence, cardiac arrhythmia1141	Occurrence, cardiac arrhythmia	leads to	Increased, Mortality1142	Decreased, Thyroxine (T4) in tissues	leads to	Altered, Amphibian metamorphosis1143	T4 in serum, Decreased	leads to	Decreased, Thyroxine (T4) in tissues1144	Abnormal, Foraging activity and behavior	leads to	Weakened, Colony1145	Weakened, Colony	leads to	Death/Failure, Colony1146	Activation, Nicotinic acetylcholine receptor	leads to	Impairment, Learning and memory1147	Activation, Nicotinic acetylcholine receptor	leads to	Abnormal, Foraging activity and behavior1148	Abnormal, Foraging activity and behavior	leads to	Abnormal, Roll change within caste1149	Abnormal, Roll change within caste	leads to	Weakened, Colony1150	Abnormal, Foraging activity and behavior	leads to	Abnormal, Role change within caste1151	Abnormal, Role change within caste	leads to	Weakened, Colony1152	N/A, Mitochondrial dysfunction 1	leads to	impaired, Hive thermoregulation1153	impaired, Hive thermoregulation	leads to	Weakened, Colony1154	N/A, Mitochondrial dysfunction 1	leads to	Weakened, Colony1155	Increased, Deformed Wing Virus levels	leads to	Weakened, Colony1156	Occurrence, renal proximal tubular necrosis	leads to	Increased, blood uric acid concentration1157	Increased, Energetic demands and therefore metabolic stress	leads to	Abnormal, Foraging activity and behavior1158	Increased, blood uric acid concentration	leads to	Increased, Oxidative Stress1159	Occurrence, renal ischemia	leads to	Increased, Oxidative Stress1160	Increased, Oxidative Stress	leads to	Occurrence, renal proximal tubular necrosis1161	Unknown, MIE	leads to	Increased, Reactive oxygen species1162	Increased, Reactive oxygen species	leads to	Increased, Oxidative Stress1163	Decreased, Thyroxine (T4) in tissues	leads to	Decreased, Triiodothyronine (T3) in tissues1164	Decreased, Triiodothyronine (T3) in tissues	leads to	Altered, Amphibian metamorphosis1165	Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo	leads to	Hemostasis, Depletion from blood of fully functional carboxylated clotting factors1166	Hemostasis, Depletion from blood of fully functional carboxylated clotting factors	leads to	Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur1167	Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle 	leads to	Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo1168	Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur	leads to	Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)1169	Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)	leads to	Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis1170	Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis	leads to	Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction1171	Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction	leads to	Impaired recruitment , Population trajectory1172	Increased, serotonin (5-HT) 1	leads to	Increased, valve movement1173	Increased, valve movement	leads to	Depletion, energy reserves1174	Increased, valve movement	leads to	Increased, water retention in foot1175	Increased, water retention in foot	leads to	Increased, foot detachment1176	Increased, foot detachment	leads to	Depletion, energy reserves1177	Increased, locomotion	leads to	Depletion, energy reserves1178	Increase, cilia movement	leads to	premature, spawning 11179	premature, spawning 1	leads to	Decreased, Reproductive Success1180	Decreased, Reproductive Success	leads to	Decline, Population1181	Depletion, energy reserves	leads to	Delayed, Sexual maturity1182	Delayed, Sexual maturity	leads to	Decreased, Reproductive Success1183	Increased, foot detachment	leads to	Increase, predation1184	Increase, predation	leads to	Decline, Population1185	Depletion, energy reserves	leads to	Increase, predation1186	Increased, serotonin (5-HT) 1	leads to	Decreased, gametogenesis1187	Increase, cilia movement	leads to	premature, Spawning 1188	Decreased, gametogenesis	leads to	Decreased, Reproductive Success1189	Increased, serotonin (5-HT) 1	leads to	Increased, locomotion1190	Induction, Incomplete ecdysis	leads to	Increased, Mortality1191	Increased, Mortality	leads to	Decreased, Population size1192	Increased, serotonin (5-HT) 1	leads to	increased or inappropriate, mantel display1193	increased or inappropriate, mantel display	leads to	Decreased, Reproductive Success1194	Anticoagulant rodenticide interferes with gamma-carboxyglutamate formation, Inhibition of p	leads to	Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei1195	Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei	leads to	Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp1196	Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp	leads to	Osteoporosis and vascular calcification, Bone deterioration1197	Inhibition, Iodotyrosine deiodinase (IYD)	leads to	Thyroidal Iodide, Decreased1198	Inhibition, Deiodinase 1	leads to	Decreased, Triiodothyronine (T3) in tissues1199	Inhibition, Deiodinase 2	leads to	Decreased, Triiodothyronine (T3) in tissues1200	Inhibition, Deiodinase 3	leads to	Increased, Triiodothyronine (T3) in tissues1201	Increased, Triiodothyronine (T3) in tissues	leads to	Altered, Amphibian metamorphosis1202	Inhibition, Pendrin	leads to	TH synthesis, Decreased1203	Inhibition, Dual oxidase	leads to	TH synthesis, Decreased1204	Activation, Hepatic nuclear receptor(s)	leads to	Increased, Hepatic thyroid hormone uptake/transport1205	Activation, Hepatic nuclear receptor(s)	leads to	Induction, Upregulation of glucuronyltransferase activity1206	Increased, Hepatic thyroid hormone uptake/transport	leads to	Increase, Biliary excretion TH glucuronide1207	Increased, serotonin (5-HT) 	leads to	Increased, mantel display1208	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"	leads to	Increased, cilia movement1209	Increased, serotonin (5-HT) 	leads to	Increased, cilia movement1210	Increased, cilia movement	leads to	premature, Spawning 1211	premature, Spawning 	leads to	Increased, Population1212	Increased, serotonin (5-HT) 	leads to	Increased, oocyte maturation1213	Increased, oocyte maturation	leads to	Increased, Reproductive Success1214	Increased, mantel display	leads to	Increased, Reproductive Success1215	Increased, Reproductive Success	leads to	Increased, Population1216	Increased, valve movement	leads to	Increased, water pumping1217	Increase, cilia movement	leads to	Increased, water pumping1218	Increase, cilia movement	leads to	Depletion, energy reserves1219	increased or inappropriate, mantel display	leads to	Depletion, energy reserves1220	increased or inappropriate, mantel display	leads to	induced, parturition1221	induced, parturition	leads to	Decreased, Reproductive Success1222	premature, Spawning 	leads to	Decreased, Reproductive Success1223	Increased, water retention in foot	leads to	Increased, valve movement1224	Increased, water pumping	leads to	Increased, water retention in foot1225	Increased, water pumping	leads to	premature, Spawning 1226	Increased, water pumping	leads to	induced, parturition1227	Increased, valve movement	leads to	Increase, predation1228	Increased, muscular waves in foot	leads to	Depletion, energy reserves1229	Activation, PPAR_	leads to	modulation, Genes/proteins that regulate hepatocyte fate1230	modulation, Genes/proteins that regulate hepatocyte fate	leads to	Increase, Mitogenic cell proliferation (hepatocytes)1231	modulation, Genes/proteins that regulate hepatocyte fate	leads to	Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci1232	Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci	leads to	Increase, Adenomas/carcinomas (hepatocellular)1233	Activation, PPAR_	leads to	Increase, Genes involved in fatty acid oxidation1234	Increase, Genes involved in fatty acid oxidation	leads to	Peptide Oxidation1235	Activation, NADPH Oxidase	leads to	Peptide Oxidation1236	Activation, PPAR_	leads to	Activation, NADPH Oxidase1237	Peptide Oxidation	leads to	Increase activation, Nuclear factor kappa B (NF-kB)1238	Increase activation, Nuclear factor kappa B (NF-kB)	leads to	modulation, Genes/proteins that regulate hepatocyte fate1239	Increase, Mitogenic cell proliferation (hepatocytes)	leads to	Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci1240	Increase, Genes involved in fatty acid oxidation	leads to	Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids1241	Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids	leads to	Peptide Oxidation1242	Inhibition, sodium channel	leads to	Decreased, sodium conductance 21243	Decreased, sodium conductance 2	leads to	Decreased, Ionotropic GABA receptor chloride channel conductance1244	Decreased, sodium conductance 2	leads to	Decreased, GABA release1245	Decreased, GABA release	leads to	Decreased, Chloride conductance1246	Activation, Estrogen receptor	leads to	Increased, ER binding to DNA (classical pathway) 1247	Increase, Cell Proliferation (Epithelial Cells)	leads to	Increased, Ductal Hyperplasia 1248	Decreased, Apoptosis (Epithelial Cells)	leads to	Increased, Ductal Hyperplasia 1249	Activation, Estrogen receptor	leads to	Increased, ER binding to T.F. to DNA (non-classical pathway)1250	Increased, ER binding to DNA (classical pathway) 	leads to	Increase, Cell Proliferation (Epithelial Cells)1251	Increased, ER binding to T.F. to DNA (non-classical pathway)	leads to	Increase, Cell Proliferation (Epithelial Cells)1252	Increased, Ductal Hyperplasia 	leads to	N/A, Breast Cancer1253	Binding, Immunophilins	leads to	Inhibition, Calcineurin Activity1254	Inhibition, Calcineurin Activity	leads to	Suppression, IL-2 and IL-4 production1255	Suppression, IL-2 and IL-4 production	leads to	Interference, nuclear localization of NFAT1256	Reduction, NFAT complex formation	leads to	Suppression, Suppression of production of cytotoxic T-cells1257	Reduction, NFAT complex formation	leads to	Suppression, Suppression of T-cell dependent antibody production1258	Suppression, Suppression of production of cytotoxic T-cells	leads to	Impairment, T-cell dependent antibody response1259	Suppression, Suppression of T-cell dependent antibody production	leads to	Increase, Increased susceptibility to infection1260	Suppression, Suppression of production of cytotoxic T-cells	leads to	Increase, Increased susceptibility to infection1261	Activation, Juvenile hormone receptor	leads to	Induction, Doublesex1 gene1262	Induction, Doublesex1 gene	leads to	Induction, Male reproductive tract1263	Induction, Male reproductive tract	leads to	Increased, Male offspring1264	Increased, Male offspring	leads to	Decline, Population1265	Decline, Population	leads to	Alteration, Food-web structures1266	Increased, Proliferation (Endothelial cells) 	leads to	Increased, Angiogenesis1267	Increased, Migration (Endothelial Cells)	leads to	Increased, Angiogenesis1268	Activation, Constitutive androstane receptor	leads to	Altered gene expression specific to CAR activation, Hepatocytes1269	Altered gene expression specific to CAR activation, Hepatocytes	leads to	Increase, Mitogenic cell proliferation (hepatocytes)1271	TRPA1 activation, TRPA1 Receptor	leads to	Opening of calcium channel, Calcium influx1272	Opening of calcium channel, Calcium influx	leads to	Sensory airway irritation, Excitation of trigeminal nerves1273	Sensory airway irritation, Excitation of trigeminal nerves	leads to	Cough, Dyspnea, Sneezing, Acute respiratory effect1274	Opening of calcium channel, Calcium influx	leads to	Excitation, Neuron nerve ending excitation1275	Excitation, Neuron nerve ending excitation	leads to	Cough, Dyspnea, Sneezing, Acute respiratory effect1276	Excitation, Neuron nerve ending excitation	leads to	Nerve excitation1277	Non-neuronal production of TNF, Epithelial irritation	leads to	Leukocyte infiltration1278	Leukocyte infiltration	leads to	Chronic Cough, Respiratory irritability1279	SP (Substance P) release, Local increase of SP	leads to	Non-neuronal production of TNF, Epithelial irritation1280	Opening of calcium channel, Calcium influx	leads to	SP (Substance P) release, Local increase of SP1281	TRPV1 activation, TRPV1	leads to	Opening of calcium channel, Calcium influx1282	Oxidization of biomolecules, Lipid bilayer and cellular proteins	leads to	TRPA1 activation, TRPA1 Receptor1283	Production of nerve growth factor , Epithelial irritation	leads to	SP (Substance P) release, Local increase of SP1284	TRPA1 activation, TRPA1 Receptor	leads to	Non-neuronal production of IL-8/CXCL1, Epithelial irritation1285	Oxidization of biomolecules, Lipid bilayer and cellular proteins	leads to	Generation of novel epitopes , Antigen presentation1286	Oxidization of biomolecules, Lipid bilayer and cellular proteins	leads to	Production of nerve growth factor , Epithelial irritation1287	Non-neuronal production of IL-8/CXCL1, Epithelial irritation	leads to	Opening of calcium channel, Calcium influx1288	Non-neuronal production of TNF, Epithelial irritation	leads to	Opening of calcium channel, Calcium influx1289	Generation of novel epitopes , Antigen presentation	leads to	Sensitization, Immune system1290	Leukocyte infiltration	leads to	Sensitization, Immune system1291	Oxidation	leads to	Generation of novel epitopes , Antigen presentation1292	Oxidation	leads to	TRPA1 activation, TRPA1 Receptor1293	Oxidation	leads to	Production of nerve growth factor , Epithelial irritation1294	Activation, Estrogen receptor	leads to	Increased, Non-genomic signaling1295	Increased, Non-genomic signaling	leads to	Increased, ER binding to T.F. to DNA (non-classical pathway)1296	Increased, ER binding to DNA (classical pathway) 	leads to	Altered, Gene Expression1297	Increased, ER binding to T.F. to DNA (non-classical pathway)	leads to	Altered, Gene Expression1298	Altered, Gene Expression	leads to	Altered, Protein Production1299	Altered, Protein Production	leads to	Increased, Oxidative Stress1300	Increased, Oxidative Stress	leads to	Increase, DNA Damage1301	Increase, DNA Damage	leads to	Altered, Gene Expression1302	Increased, Non-genomic signaling	leads to	Altered, Gene Expression1303	Altered, Protein Production	leads to	Increased, Proliferation (Endothelial cells) 1304	Altered, Protein Production	leads to	Decreased, Apoptosis (Epithelial Cells)1305	Altered, Protein Production	leads to	Increased, Motility1306	Increased, Motility	leads to	Increased, Invasion1307	Activation, Estrogen receptor	leads to	Increased, Second Messenger Production1308	Increased, Second Messenger Production	leads to	Increased, Non-genomic signaling1309	Desensitization, Nicotinic acetylcholine receptor	leads to	Altered, Ca2+-calmodulin activated signal transduction1310	Altered, Ca2+-calmodulin activated signal transduction	leads to	Impairment, Learning and memory1311	N/A, Mitochondrial dysfunction 1	leads to	Altered, Ca2+-calmodulin activated signal transduction1312	Goblet cell hyperplasia	leads to	Increase, Mucin production1313	Occurrence, Metaplasia of goblet cells	leads to	Increase, Mucin production1314	Chronic, Mucus hypersecretion	leads to	Decrease, Lung function1315	Increase, Mucin production	leads to	Chronic, Mucus hypersecretion1316	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"	leads to	Increased, muscular waves in foot1317	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"	leads to	Increased, valve movement1318	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"	leads to	Increase, cilia movement1319	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"	leads to	increased mantel display1320	Increased, valve movement	leads to	induced spawning1321	Increase, cilia movement	leads to	induced spawning1322	increased mantel display	leads to	Induced parturition1323	Induced parturition	leads to	Decreased, Reproductive Success1324	induced spawning	leads to	Decreased, Reproductive Success1325	induced spawning	leads to	Increased, Reproductive Success1326	Induced parturition	leads to	Increased, Reproductive Success1327	Increased, serotonin (5-HT) 	leads to	Increased, valve movement1328	Increased, oocyte maturation	leads to	induced spawning1329	Increased, cilia movement	leads to	induced spawning1330	DNA topoisomerase II “poisons”	leads to	MLL translocation1331	MLL translocation	leads to	IFL1332	Increased, serotonin (5-HT) 	leads to	Increased, muscular waves in foot1333	Increased, serotonin (5-HT) 	leads to	Increase, cilia movement1334	Increased, valve movement	leads to	Induced parturition1335	Increase, cilia movement	leads to	Induced parturition1336	Increased, serotonin (5-HT) 	leads to	increased mantel display1337	"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"	leads to	Increased, oocyte maturation1338	Decompartmentalization	leads to	Mitochondrial impairment1339	Direct mitochondrial inhibition	leads to	Mitochondrial impairment1340	narcosis	leads to	Mitochondrial impairment1341	Mitochondrial impairment	leads to	Apoptosis1342	Mitochondrial impairment	leads to	Necrosis1343	Activation, EcR	leads to	Induction, E75b gene1344	Induction, E75b gene	leads to	Suppression, Ftz-f1 gene1345	Suppression, Ftz-f1 gene	leads to	Reduction, Release of circulating ETH1346	Reduction, Release of circulating ETH	leads to	Reduction, Release of circulating CCAP1347	Reduction, Release of circulating CCAP	leads to	Reduction, Ecdysis motoneuron bursts1348	Reduction, Ecdysis motoneuron bursts	leads to	Reduction, Excitatory postsynaptic potential1349	Reduction, Excitatory postsynaptic potential	leads to	Reduction, Abdominal muscle contraction1350	dimerization, AHR/ARNT	leads to	Increase, COX-2 expression1351	Increase, COX-2 expression	leads to	Altered, Cardiovascular development/function1352	Altered, Cardiovascular development/function	leads to	Increase, Mortality1353	Inactivation of PPAR_	leads to	Activation of TGF-_ signaling1354	Activation of TGF-_ signaling	leads to	Differentiation of Myofibroblast1355	Activation of TGF-_ signaling	leads to	Expression of Collagen1356	Differentiation of Myofibroblast	leads to	Production of _-smooth muscle actin1357	Expression of Collagen	leads to	Collagen Deposition1358	Production of _-smooth muscle actin	leads to	Lung fibrosis1359	Collagen Deposition	leads to	Lung fibrosis1360	Activation, NADPH Oxidase	leads to	ROS formation1361	ROS formation	leads to	Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK1362	Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK	leads to	Increased, DNA Damage-Repair1363	Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK	leads to	Damaging, Mitochondria1364	Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK	leads to	Activation, HIF-11365	Activation, HIF-1	leads to	Apoptosis1366	Increased, DNA Damage-Repair	leads to	Apoptosis1367	Damaging, Mitochondria	leads to	Apoptosis1368	Apoptosis	leads to	Reproductive failure1369	Activation, JAK/STAT pathway	leads to	Activation, TGF-beta pathway1370	Activation, TGF-beta pathway	leads to	Reproductive failure1371	Up Regulation, SREBF2	leads to	Up Regulation, Unsaturated fatty acid1372	Up Regulation, Unsaturated fatty acid	leads to	Perturbation of cholesterol1373	Down Regulation, GSS and GSTs gene	leads to	Glutathione synthesis1374	Glutathione synthesis	leads to	Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene1375	Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene	leads to	Perturbation of cholesterol1376	Down Regulation, GSS and GSTs gene	leads to	Glutathione homeostasis1377	Perturbation of cholesterol	leads to	Hepatotoxicity1378	Glutathione homeostasis	leads to	Hepatotoxicity1379	Peptide Oxidation	leads to	Activation, JNK1380	Activation, JNK	leads to	Activation, FOXO1381	Activation, FOXO	leads to	Inhibition, Wnt pathway1382	Inhibition, Wnt pathway	leads to	Defect of Embryogenesis1383	Defect of Embryogenesis	leads to	Reproductive failure1384	Agonism, Androgen receptor	leads to	Reduction, 17beta-estradiol synthesis by ovarian granulosa cells1385	Agonism, Androgen receptor	leads to	Reduction, Vitellogenin synthesis in liver1386	Reduction, Plasma 17beta-estradiol concentrations	leads to	Reduction, Plasma vitellogenin concentrations1387	T4 in serum, Decreased	leads to	Hippocampal gene expression, Altered 1388	T4 in serum, Decreased	leads to	Hippocampal anatomy, Altered 1389	T4 in serum, Decreased	leads to	Hippocampal Physiology, Altered1390	Increase, insulin	leads to	Activation, insulin receptor 1391	Activation, insulin receptor 	leads to	Activation, mTORC21392	Activation, mTORC2	leads to	Activation, AKT1393	Activation, mTORC2	leads to	Activation, mTORC11394	Activation, AKT	leads to	Activation, SREBP-11395	Activation, mTORC1	leads to	Activation, L-FABP 1396	Activation, mTORC1	leads to	Activation, HSD17B41397	Activation, SREBP-1	leads to	Activation, FXR1398	Activation, AKT	leads to	Activation, mTORC11399	Activation, mTORC1	leads to	Activation, SREBP-11400	Activation, AKT	leads to	Activation, L-FABP 1401	Activation, L-FABP 	leads to	Increase, cytosolic fatty acid1402	demethylation, PPARg promoter	leads to	Activation, SREBP-11403	Activation, SREBP-1	leads to	Activation, SCD-11404	Activation, SCD-1	leads to	Increased, lipogenesis1405	Increased, lipogenesis	leads to	Increase, cytosolic fatty acid1406	Activation, NRF2	leads to	Activation, FXR1407	Activation, FXR	leads to	Activation, SHP1408	Activation, FXR	leads to	Activation, PPAR_1409	Activation, SHP	leads to	Activation, PPAR_1410	Activation, PPAR_	leads to	Activation, HSD17B41411	Activation, HSD17B4	leads to	Inhibition, Mitochondrial fatty acid beta-oxidation1412	Activation, SHP	leads to	Inhibition, LXR1413	Inhibition, LXR	leads to	Inhibition, PPAR alpha1414	Activation, SHP	leads to	Inhibition, LRH-11415	Activation, HSD17B4	leads to	Induction, fatty acid beta-oxidation1416	Induction, fatty acid beta-oxidation	leads to	Inhibition, Steatosis1417	Induction, fatty acid beta-oxidation	leads to	Decrease, cytosolic fatty acid1418	Activation, PI3K	leads to	Activation, AKT1419	Activation, PI3K	leads to	Activation, L-FABP 1420	Activation, PI3K	leads to	Activation, aPKC1421	Activation, aPKC	leads to	Activation, SREBP-11422	Activation, FAS	leads to	Increased, lipogenesis1423	Activation, L-FABP 	leads to	demethylation, PPARg promoter1424	demethylation, PPARg promoter	leads to	Activation, FAS1425	Activation, LRH-1	leads to	Activation, FAS1426	Decreased, serotonin transporter activity	leads to	Increased, intracellular sodium (Na+)1427	Decreased, serotonin transporter activity	leads to	Increased, intracellular chloride (Cl-)1428	Decreased, serotonin transporter activity	leads to	Decreased, extracellular Na+ 1429	Decreased, serotonin transporter activity	leads to	Decreased, extracellular chloride (Cl-)1430	Decreased, serotonin transporter activity	leads to	Increased, extracellular serotonin1431	Decreased, serotonin transporter activity	leads to	Decreased, intracellular serotonin1432	Decreased, intracellular serotonin	leads to	Decreased, packaged serotonin1433	Decreased, packaged serotonin	leads to	Decreased, synaptic release1434	Decreased, synaptic release	leads to	Decreased, extracellular serotonin1435	Decreased, extracellular serotonin	leads to	Increased, 5-HT31436	Decreased, extracellular serotonin	leads to	Inactivated, 5-HTR1437	Decreased, extracellular serotonin	leads to	Activation, 5-HT2A1438	Activation, 5-HT2A	leads to	Activate, PLC1439	Activate, PLC	leads to	Increase, inositol triphosphate1440	Increase, inositol triphosphate	leads to	Increase, intracellular calcium1441	Increase, intracellular calcium	leads to	Activate, calmodulin1442	Activate, calmodulin	leads to	Increase, myosin light chain phosphorylation1443	Increase, myosin light chain phosphorylation	leads to	Increase, vascular smooth muscle contraction1444	Increase, vascular smooth muscle contraction	leads to	Increase, hypertension1445	Increased, 5-HT3	leads to	Increased, seizure1446	Inactivated, 5-HTR	leads to	Reduce expression, BDNF1447	Reduce expression, BDNF	leads to	Decreased, neuroplasticity1448	Decreased, neuroplasticity	leads to	Increased, agitation1449	Decreased, neuroplasticity	leads to	Increased, depression1450	Increase, cortisone	leads to	Activation, Glucocorticoid Receptor1451	Activation, Glucocorticoid Receptor	leads to	Reduced, BDNF1452	Activated, presynaptic neuron 1	leads to	Increased, glutamate1453	Increased, glutamate	leads to	Activated, NMDA receptor1454	Activated, NMDA receptor	leads to	Increased, intracellular sodium (Na+)1455	Increased, intracellular sodium (Na+)	leads to	Activated, voltage-gated sodium channel1456	Treat, carbamazepine	leads to	Inhibit, voltage-gated sodium channel1457	Activated, voltage-gated sodium channel	leads to	Activated, membrane depolarization1458	Activated, membrane depolarization	leads to	Increased, hippocampal hyperdepolarization1459	Increased, hippocampal hyperdepolarization	leads to	Increase, seizure1460	Increase, seizure	leads to	Increased, epilepsy1461	Activate, presynaptic neuron 2	leads to	Increase, GABA1462	Increase, GABA	leads to	Activate, GABA-A receptor1463	Increased, RDX dose	leads to	Activate, GABA-A receptor1464	Activate, GABA-A receptor	leads to	Increased, intracellular chloride (Cl-)1465	Increased, intracellular chloride (Cl-)	leads to	Inactive, membrane depolarization1466	Increase, Excessive ROS generation	leads to	Peptide Oxidation1467	Peptide Oxidation	leads to	Increase, DNA Damage1468	Increase, DNA Damage	leads to	Increase, Apoptosis1469	Increase, Apoptosis	leads to	Decrease, Oogenesis1470	Decrease, Oogenesis	leads to	Decrease, Ovulation1471	Decrease, Ovulation	leads to	Decrease, Fertility1472	Decrease, Fertility	leads to	Decrease, Population trajectory1473	Increase, angiogenesis	leads to	Inhibit, gastric ulcer formation1474	Increase, platelet aggregation	leads to	Inhibit, gastric ulcer formation1475	Activate, mucosal defense	leads to	Inhibit, gastric ulcer formation1476	Activate, leukocyte 	leads to	Activated, gastric ulcer formation1477	Increase, leukocyte adherence	leads to	Activate, leukocyte 1478	Activation, PTGS-2	leads to	Decrease, leukocyte adherence1479	Activation, PTGS-2	leads to	Increase, angiogenesis1480	Activation, PTGS-1	leads to	Increase, platelet aggregation1481	Activation, PTGS-1	leads to	Increase, mucosal blood flow1482	Activation, PTGS-1	leads to	Increase, mucous1483	Activation, PTGS-1	leads to	Increase, bicarbonate 1484	Increase, bicarbonate 	leads to	Activate, mucosal defense1485	Increase, mucous	leads to	Activate, mucosal defense1486	Increase, mucosal blood flow	leads to	Activate, mucosal defense1487	Increase, ammonium (NH4+)	leads to	Decrease, surfactant1488	Activate, phospholipase	leads to	Decrease, surfactant1489	Increase, surfactant	leads to	Activate, mucosal defense1490	Altered, Cardiovascular development/function	leads to	Increased, Mortality1491	Decreased, Population trajectory	leads to	Increased, Mortality1492	Activation, AhR	leads to	Increased, Mortality1493	CYP7B activity, inhibition	leads to	7_-hydroxypregnenolone synthesis in the brain, decreased1494	CYP7B activity, inhibition	leads to	Locomotor activity, decreased1495	7_-hydroxypregnenolone synthesis in the brain, decreased	leads to	Locomotor activity, decreased1496	7_-hydroxypregnenolone synthesis in the brain, decreased	leads to	Dopamine release in the brain, decreased1497	Dopamine release in the brain, decreased	leads to	Locomotor activity, decreased1498	7_-hydroxypregnenolone synthesis in the brain, decreased	leads to	Sexual behavior, decreased1499	Sexual behavior, decreased	leads to	Decreased, Reproductive Success1500	Locomotor activity, decreased	leads to	Decreased, Reproductive Success1501	Decreased, Reproductive Success	leads to	Decreased, Population trajectory1502	Dopamine release in the brain, decreased	leads to	Sexual behavior, decreased1503	Inhibition, Na+/I- symporter (NIS)	leads to	Impairment, Learning and memory1504	TH synthesis, Decreased	leads to	BDNF, Reduced1505	TH synthesis, Decreased	leads to	GABAergic interneurons, Decreased1506	TH synthesis, Decreased	leads to	Impairment, Learning and memory1507	BDNF, Reduced	leads to	Impairment, Learning and memory1508	Inhibition, Calcineurin Activity	leads to	Interference, nuclear localization of NFAT1509	Reduction, NFAT complex formation	leads to	Suppression, IL-2 and IL-4 production1510	Suppression, IL-2 and IL-4 production	leads to	Impairment, T-cell dependent antibody response1511	Inactivated, 5-HTR	leads to	Reduced, BDNF1512	Activation of Cyp2E1 in the liver	leads to	Oxidative Stress 1513	Oxidative Stress 	leads to	Hepatocytotoxicity1514	Hepatocytotoxicity	leads to	Hepatocellular Regenerative Proliferation 1515	Activation of Cyp2E1 in the liver	leads to	Hepatocytotoxicity1516	Oxidative Stress 	leads to	Liver Cancer1517	Hepatocytotoxicity	leads to	Liver Cancer1518	Hepatocellular Regenerative Proliferation 	leads to	Liver Cancer1519	Decreased, extracellular serotonin	leads to	Decreased, synaptic release1520	Inhibit, serotonin transporter activity	leads to	Decreased, serotonin transporter activity1521	Increased, extracellular serotonin	leads to	Decreased, extracellular serotonin1522	Increased, glucocorticoid receptor activity	leads to	Reduced, BDNF1523	Reduced, BDNF	leads to	Decreased, neuroplasticity1524	Increased, serotonin transporter activity	leads to	Increased, intracellular serotonin1525	Increased, intracellular serotonin	leads to	Increased, packaged serotonin1526	Increased, packaged serotonin	leads to	Increased, synaptic release1527	Increased, synaptic release	leads to	Increased, extracellular serotonin1528	Increased, serotonin transporter activity	leads to	Decreased, extracellular serotonin1529	Increased, extracellular serotonin	leads to	Decreased, 5-HT31530	Decreased, 5-HT3	leads to	Increased, seizure1531	Increased, extracellular serotonin	leads to	Activation, 5-HT2A1532	Reduced, PTGS1 function	leads to	Reduced, platelet aggregation1533	Reduced, platelet aggregation	leads to	Activated, gastric ulcer formation1534	Reduced, PTGS1 function	leads to	Decreased, mucosal blood flow1535	Decreased, mucosal blood flow	leads to	Reduced, mucosal defense1536	Reduced, mucosal defense	leads to	Activated, gastric ulcer formation1537	Reduced, PTGS1 function	leads to	Decreased, mucous1538	Decreased, mucous	leads to	Reduced, mucosal defense1539	Reduced, PTGS1 function	leads to	Decreased, bicarbonate1540	Decreased, bicarbonate	leads to	Reduced, mucosal defense1541	Reduced, PTGS2 function	leads to	Decreased, angiogenesis1542	Decreased, angiogenesis	leads to	Activated, gastric ulcer formation1543	Reduced, PTGS2 function	leads to	Increased, leukocyte adherence1544	Increased, leukocyte adherence	leads to	Increased, leukocyte activation1545	Increased, leukocyte activation	leads to	Activated, gastric ulcer formation1546	Helicobacter pylori infection	leads to	Increase, ammonium (NH4+)1547	Decrease, surfactant	leads to	Reduced, mucosal defense1548	Reduced, mucosal defense	leads to	Helicobacter pylori infection1549	Increased, hippocampal hyperdepolarization	leads to	Increased, seizure1550	Increased, seizure	leads to	Increased, epilepsy1551	Reduced, presynaptic neuron 2 activity	leads to	Decreased, GABA1552	Decreased, GABA	leads to	Reduced, GABA-A receptor activation1553	Reduced, GABA-A receptor activation	leads to	Decreased, intracellular chloride1554	Decreased, intracellular chloride	leads to	Activated, membrane depolarization1555	Increased, RDX dose	leads to	Reduced, GABA-A receptor activation1556	NFE2/Nrf2 repression	leads to	Reduced, FXR activity1557	Reduced, FXR activity	leads to	Reduced, SHP activity1558	Reduced, SHP activity	leads to	Activated, LXR1559	Activated, LXR	leads to	Reduced, PPARalpha1560	Reduced, PPARalpha	leads to	Reduced, HSD17B4 activity1561	Reduced, HSD17B4 activity	leads to	Reduced, fatty acid beta oxidation1562	Reduced, fatty acid beta oxidation	leads to	Increased, steatosis1563	Mu Opioid Receptor Agonism	leads to	Release of G Proteins1564	Release of G Proteins	leads to	Opening of GIRK channels1565	Opening of GIRK channels	leads to	hyperpolarisation, neuron1566	hyperpolarisation, neuron	leads to	Analgesia1567	Altered, Cardiovascular development/function	leads to	Increase, Embryolethality1568	Release of G Proteins	leads to	Inhibition of Ca Channels1569	Inhibition of Ca Channels	leads to	Inhibition of neurotransmitter release1570	Inhibition of neurotransmitter release	leads to	Analgesia1571	Serotonin 1A Receptor Agonism	leads to	Release of G Proteins1572	hyperpolarisation, neuron	leads to	Anti-depressant Activity1573	Inhibition of neurotransmitter release	leads to	Anti-depressant Activity1574	SP (Substance P) release, Local increase of SP	leads to	Nerve excitation1575	Excitation, Neuron nerve ending excitation	leads to	SP (Substance P) release, Local increase of SP1576	TRPA1 activation, TRPA1 Receptor	leads to	Generation of novel epitopes , Antigen presentation1577	SP (Substance P) release, Local increase of SP	leads to	Leukocyte infiltration1578	Excitation, Neuron nerve ending excitation	leads to	Increased CGRP1579	Increased CGRP	leads to	Nerve excitation1580	Increased CGRP	leads to	Increase, hypertension1581	Increase, hypertension	leads to	Chronic Cough, Respiratory irritability1582	Excitation, Neuron nerve ending excitation	leads to	Irritation induced sneezing1583	Excitation, Neuron nerve ending excitation	leads to	Increased NKA1584	Increased NKA	leads to	Nerve excitation1585	Increased NKA	leads to	Leukocyte infiltration1586	Increased CGRP	leads to	Leukocyte infiltration1587	Increased CGRP	leads to	Chronic Cough, Respiratory irritability1588	Sensing of the stressor	leads to	Pro-inflammatory cytokines increased1589	Pro-inflammatory cytokines increased	leads to	SAA production increased1590	SAA production increased	leads to	HDL-SAA formation1591	HDL-SAA formation	leads to	Systemic cholesterol increased1592	Systemic cholesterol increased	leads to	Foam cell formation1593	HDL-SAA formation	leads to	Foam cell formation1594	Foam cell formation	leads to	Plaque progression1595	Increase, Excessive ROS generation	leads to	Increase, DNA Damage1596	Increase, Apoptosis	leads to	Increase, Follicular atresia1597	Increase, Follicular atresia	leads to	Decrease, Oogenesis1598	Increase, Excessive ROS generation	leads to	Increase, Lipid peroxidation1599	Increase, Lipid peroxidation	leads to	Increase, Uncoupling of OXPHOS1600	Increase, Uncoupling of OXPHOS	leads to	Decrease, Mitochondrial ATP production1601	Decrease, Mitochondrial ATP production	leads to	Decrease, Oogenesis1602	Increase, ROS production	leads to	Increase, DNA Damage1603	Increase, ROS production	leads to	Increase, Lipid peroxidation1606	Activation, LXR alpha	leads to	Increased, De Novo FA synthesis1607	Increased, De Novo FA synthesis	leads to	Increased, Liver Steatosis1608	demethylation, PPARg promoter	leads to	Activation of specific nuclear receptors, PPAR-gamma activation1609	Activation of specific nuclear receptors, PPAR-gamma activation	leads to	increased adipogenesis1610	activation of CEBPA	leads to	Activation of specific nuclear receptors, PPAR-gamma activation1611	activation of CEBPA	leads to	increased adipogenesis1612	increased adipogenesis	leads to	obesity1613	chronic high fat diet	leads to	decreased dopamine1614	decreased dopamine	leads to	decreased reward1615	decreased reward	leads to	decreased DNA methylation of tyrosine hydroxylase1616	decreased reward	leads to	decreased methylation of dopamine transporter promoter1617	decreased reward	leads to	decreased dopamine1618	decreased DNA methylation of tyrosine hydroxylase	leads to	obesity1619	decreased methylation of dopamine transporter promoter	leads to	obesity1620	decreased DNA methylation of tyrosine hydroxylase	leads to	decreased dopamine1621	decreased methylation of dopamine transporter promoter	leads to	decreased dopamine1622	Sustained inflammatory cytokine release	leads to	Increased, secretion of local growth factors1623	Increase, ROS production	leads to	Increased, secretion of local growth factors1624	Increased, secretion of local growth factors	leads to	Differentiation of fibroblasts1625	Increased, secretion of local growth factors	leads to	EMT1626	Differentiation of fibroblasts	leads to	Expression of Collagen1627	EMT	leads to	Expression of Collagen1628	Collagen Deposition	leads to	Accumulation, Collagen1629	Accumulation, Collagen	leads to	Pulmonary fibrosis1630	Cell damage sensing	leads to	Sustained inflammatory cytokine release1631	Cell damage sensing	leads to	Increase, ROS production1632	Cell damage sensing	leads to	Increased, secretion of local growth factors1633	Sustained inflammatory cytokine release	leads to	Differentiation of fibroblasts1634	DNA topoisomerase II “poisons”	leads to	DSB1635	DSB	leads to	MLL translocation1636	Thiol protein adducts	leads to	Inhibition of lysyl oxidase1637	Inhibition of lysyl oxidase	leads to	Reduction of collagen crosslinking1638	Reduction of collagen crosslinking	leads to	Weak collagen matrix1639	Weak collagen matrix	leads to	Notochord malformation1640	Notochord malformation	leads to	Reduced, Swimming performance1641	Reduced, Swimming performance	leads to	Growth, reduction1642	Reduced, Swimming performance	leads to	Decreased, survival1643	Decrease, histaminergic neuron excitation	leads to	Impairment, Learning and memory1644	Impairment, Learning and memory	leads to	Decreased, locomotion1645	GR Agonist, Activation	leads to	Increased apoptosis, decreased Leydig Cells 1646	GR Agonist, Activation	leads to	Repressed expression of steroidogenic enzymes 1647	Increased apoptosis, decreased Leydig Cells 	leads to	Reduction, Testosterone synthesis in Leydig cells1648	Repressed expression of steroidogenic enzymes 	leads to	Reduction, Testosterone synthesis in Leydig cells1649	Reduction, testosterone level	leads to	Decreased sperm quantity or quality in the adult, Decreased fertility 1650	Decreased sperm quantity or quality in the adult, Decreased fertility 	leads to	impaired, Fertility1651	TGFbeta1 activation	leads to	TGFbeta pathway activation1652	TGFbeta pathway activation	leads to	Differentiation of fibroblasts1653	TGFbeta pathway activation	leads to	EMT1654	Differentiation of fibroblasts	leads to	Accumulation, Collagen1655	EMT	leads to	Accumulation, Collagen			Help			About			FAQ			Metrics 			